Category: Publications

Parent category to all problems relating to the physical aspect of the body

  • AUTO-SANGUIS THERAPY

    According to the teachings of Reckeweg’s homotoxicology, virtually every illness may be defined as either a defensive reaction by the organism against toxins or as the expression of toxic damage. It follows, therefore, that the blood of each patient contains those pathogenic poisons (homotoxins) typical of the disease from which that patient suffers.

    Through withdrawing a patient’s blood, then homeopathically potentising it over several levels and subsequently re-introducing it by means of hypodermic injection, Reckeweg holds that precisely these pathogenic poisons undergo modification to yield a homeopathically active therapeutic agent ideal for application in stimulation therapy. This agent stimulates the body’s defense systems thus increasing detoxification and promoting the healing process.

    According to Burgi’s Principle, the injection of appropriate homeopathic preparations intensifies efficacy of the potentised auto-sanguis blood to an even higher degree.

    Auto-sanguis therapy is a treatment designed to exert a counteractive effect against exogenic and endogenic homotoxins (including toxic deterioration of by-products from the body’s own cells), thus promoting the healing of chronic disease in harmony with the laws of nature.


    1. Withdraw 2–3 cc of the patient’s blood
    2. Expell contents of syringe
    3. Using the syringe and needle initially used for blood withdrawal, aspirate the appropriate Heel remedy (injeel, suis organ, etc.). It is best to use no more than 3 remedies. Once the remedy is in the syringe, cap the syringe and shake vigorously, about 10 times to potentise the mixture.

    This is the first potentisation which is then injected into the patient s.c. or i.m. (and i.a. & i.p. in an experimental nature).

    Intravenous injection is contraindicated in auto-sanguis therapy, as the degree of potentisation would be lost, and the intended action on the immune system would become questionable.

    Potentisation can be carried out up to 5 times. The number of stages you select should be adjusted according to your prognosis, professional judgment and familiarity with the patient.


    CONDITIONS THAT MAY BENEFIT FROM AUTO-SANGUIS THERAPY:

    • Iatrogenic conditions
    • Chronic viral and bacterial infections
    • Precancerous stages
    • Hepatic damage
    • Migraine
    • Chronic eczema
    • Bronchial asthma
    • Duodenal and gastric ulcers
    • Arthrosis
    • Lymphatic diathesis

    PROTOCOL FROM A CASE STUDY
    Case study by: Drs Ivo Bianchi & Jo Serrentino

    RE: 40 year old female Caucasian

    CONDITION: Lower back pain due to strain and possible cervical hernia. X-rays showed a small deviation (less than 5 degrees) of vertebra #5, without arthrosis or calcification. This deviation was congenital and no damage seemed evident. The condition worsened because of irritation of the sciatic nerve due to overexertion.

    PROCEDURE: 1–2 cc of patient’s blood was drawn into a sterile syringe. The blood was discarded, leaving only minute traces of the patient’s blood in the syringe. 2 cc of Discus compositum, 2 cc of Traumeel and 2 cc of Zeel were then aspirated into the emptied syringe (that still had traces of the patient’s blood). The injection was given s.c. in the region of the 5th vertebra.

    RESULTS: Although this patient’s condition was not serious or degenerative, but rather from injury, it was very painful and restricted movement. A treatment to relieve and, mostly halt the progress of the condition, was imperative. The auto-sanguis treatment was followed with intravenous injection of Traumeel and with the oral administration of Zeel, Traumeel and Discus comp. fragmented over two weeks.

    The patient claimed relief almost immediately, with a slight exacerbation within hours of the treatment lasting about 4 hours. The following day the patient was able to resume normal movement which progressively improved to full recovery without recurrence within the three year follow up period.

  • Introduction to Neural Therapy

    by HEEL Medical – Scientific Department

    What does neural therapy involve?

    Neural therapy involves curative procedures which act via the autonomic nervous system. Techniques of neural therapy were developed from procedures applied for local anesthesis by the two brothers and general practitioners Dr. Ferdinand Huneke and Dr. Walter Huneke, both medical doctors in Düsseldorf.

    Neural (Greek)

    Of, relating to, or affecting a nerve or the nervous system.

    Neuron

    Nerve cell, nerve tracts, neuron theory

    Neuron theory

    The original version of the neuron theory, as published by Ramon y Cajal in 1934, stated that each nerve cell (i.e., neuron) represents an anatomical, genetic, functional, and regenerative unit.

    The latest insights gained from electron-microscopic findings have confirmed the reality of synapses as physically and anatomically verified sites of junction: between two neurons (i.e., an interneuronal synapse) and between a neuron (peripheroreceptor) and the locus of action (i.e., a neuro-receptor synapse). These insights, in conjunction with complementary findings, represent the confirmed scientific basis for the entire fields of neurohistology, neurophysiology, and neuropathology.

    The significance of neural therapy: Neural therapy involves curative techniques administered via the autonomic nervous system. The autonomic nervous system is a functional unit which includes the neurohumoral regulatory system in its overall mode of reflectoral operation. The autonomic nervous system encompasses the sympathetic nervous system, the parasympathetic nervous system, and the basic autonomic neural system. This basic autonomic neural system is the interstitial, soft connecting tissue which fills all organ interstices. It is composed of cells, nerves, capillaries, and extracellular fluid. This system plays the role of a communicator in the overall arrangement which enables each cell in the body to be in connection with every other cell. The autonomic nervous system is that part of the entire central nervous system which is of significance for the maintenance and reproduction of the particular organism involved. The autonomic nervous system primarily serves for control of the inner milieu. Since the control loops of the autonomic and somatic nervous systems are multiply interlinked at all synapse stages of the central nervous system, the functioning of the autonomic nervous system is not in fact strictly autonomous in nature.

    The autonomic nervous system differs from the somatic nervous system in the following significant aspect:

    • Connections to the periphery are not uniformly present.
    • These connections are also subject to interruption by intermediate ganglionic stations (in which the ganglia are groups of nerve cell bodies). In the autonomic nervous system, sympathetic and parasympathetic ganglia are involved.

    Human life is possible only in conjunction with the hermetic control of all regulation mechanisms. The pathways of the autonomic nervous system have the function of passing stimuli. Excessive stimuli disturb or block the development of energy and, in turn, the distribution of this energy. All neural therapeutic methods feature the introduction of energy to the impaired tissue, or they effect removal of the blockage by energy transfer. These procedures, however, also initiate reactions which are capable of eliminating damage which has already occurred. The body’s defense system, with its mechanisms of self-healing, is thereby stimulated to action.

    All neural therapeutic techniques in the broad sense utilize this approach: acupuncture, chirotherapy, cutaneous and other types of stimulation, and cupping. And the same applies for neural therapy in the narrow sense: concerted injection therapy with local anesthetic.

    HISTORICAL SUMMARY OF NEURAL THERAPY

    Neural therapy by means of local anesthetic was discovered orientationally by Ferdinand and Walter Huneke. The Huneke brothers, both medical doctors from a family of physicians, had attempted unsuccessfully for years to treat their sister’s migraine attacks.

    Atrophanyl, a new medication for rheumatism, was introduced onto the market in 1925. On the advice of a colleague, Ferdinand Huneke treated his sister by intravenous injection of the new preparation. The therapy immediately interrupted the migraine attack, with all its accompanying symptoms. Only one single subsequent administration, with the same success, was required to completely free his sister of her long-term suffering.

    The two brothers were naturally impressed by the success of their treatment, but they could not explain the effects. They eventually determined, however, that Atrophanyl was available in the following two types:

    • For intravenous administration, without 2% addition of cocaine
    • For intramuscular administration, with 2% addition of cocaine

    In his treatment of his sister, Ferdinand had confused the two solutions and had mistakenly administered the procaine solution intravenously – a form of administration which had until that time been expressly forbidden. It was believed then that procaine could damage important centers in the brain.

    Motivated by the unexplained success of the therapy, the brothers then began to separately study the causative factors behind the accidental cure.

    The two brothers independently discovered that the positive effect of the procaine was not only associated with the mode of administration (i.e., intravenous injection), but that the determining criterion for the therapeutic results was most probably the specific point of the injection. They wondered whether previously unknown reflex-type reactions could possibly act via Head’s zones.

    Beginning with these findings, Ferdinand and Walter Huneke used injections administered at particular points to treat conditions of pain in the respectively segment-associated areas of the body. They named their technique “therapeutic anesthesia,” until Kibler, a friend, proposed a better name: “segment therapy with local anesthesia.”

    In 1928, the Huneke brothers published their findings in Medizinische Welt under the title, “Unexpected Remote Therapeutic Effects of Local Anesthesia.”

    Neural therapy as developed by the Hunekes is administered in two forms:

    • A. Segment therapy: Concerted injections of anesthetic into the segmental area associated with the illness.
    • B. Elimination of a focal disorder: Rendering a causal focal disorder ineffective by means of a neural therapeutic agent acts as causal therapy, with the elimination of complaints and pain in seconds (the so-called Huneke phenomenon), including pain without segmental association.

    Definition of focal disorder

    A focal disorder is chronically altered tissue which causes remote disorders via neural paths. A focal disorder is considered to be any pathological alteration which possesses the ability to cause remote disorders beyond its immediate locale.

    Location of focal disorders

    Pinpointing of the focus responsible for a disorder begins with preparation of a concerted case history, and includes systematic injections at potential foci.

    SEGMENT THERAPY

    Segment therapy is based on the insight that all parts of a bodily segment respond by reflection, as a unit, to particular processes. Stimulation pulses proceed from the body’s periphery, via the spinal cord, to the segment-associated organ, and vice versa. Pulses also travel along the dermato-visceral reflex path, or from an organ via the spinal cord to other organs—as well as along the viscero-visceral reflex path.

    IMPORTANT: In all cases it is the entire human being which becomes ill, and never only one isolated organ. Concerted neural therapy not only interrupts pathological reflex paths, but also normalizes all autonomic neural functions through repolarization of the stimulus-disordered cell-membrane potentials.

    • Most important therefore is the point at which the injection is performed, and only to a lesser degree the particular medication which is administered. Segment therapy is genuine treatment in the original sense of the Latin origin “tractare,” to handle—a laying on of the hand.

    Head’s zones

    These zones were named for the work of Sir Henry Head, a London neurologist (1861–1940). These are hyperesthetic-hyperalgesic zones which appear on the surface of the human trunk in conjunction with disorders of certain inner organs, and which are characterized by heightened cutaneous sensitivity. This phenomenon has been explained by the fact that these cutaneous zones are provided with their sensitive innervation (nerve supply) from the same neural segments which supply the disordered organ.

    Disordered sensitivity is also often found together with alterations of muscle tone (defense musculaire—for example, appendicitis), involving the viscero-cutaneous reflex.

    What is meant by “chronically altered tissue”? Non-vital teeth, points of focal infection, tonsils as foci, scars on the surface of the skin or deeper in the body, scars on bones, foreign bodies, chronically inflamed organs (e.g., appendicitis chronica), and residual conditions after inflammatory processes which have subsided; e.g., in the ears and sinus cavities, at the gall bladder, at the appendix, in the female genital tract, and in the prostate.

    HUNEKE’S INSTANTANEOUS PHENOMENON

    In 1941, Ferdinand Huneke discovered that there are foci located on neural paths and not subject to any segmental assignment, yet capable of initiating and maintaining certain illnesses. These foci can be rendered ineffective in the neural-therapeutic sense by the concerted administration of local anesthetics. The disorders caused by the treated foci will then immediately vanish as a result of Huneke’s so-called flash phenomenon.

    Huneke’s flash phenomenon is involved if all three of the following conditions are met:

    1. All symptoms vanish instantaneously and completely.
    2. Freedom from the symptoms continues for at least twenty hours.
    3. The above phenomena are repeated with recurring symptoms.

    If all conditions are met, injections are continued at intervals of one week—with the periods between injections gradually lengthened—until a complete cure is achieved.

    Important: If, however, significant improvement is not achieved by injections into the segment, and if the flash phenomenon is not observed in the suspected focus, then injections at this point are futile, and the search for the proper focus must continue.

    N.B.: The most important factor in neural therapy is the point of injection, and not the particular medication injected.

    THE TECHNIQUES OF NEURAL THERAPY

    Instruments required

    • Single-use cannulae
    • Single-use syringes (5‑ml plastic syringes have proved most effective for focal disorders)
    • A neural therapeutic agent.

    Dosage and manner of application will vary considerably from case to case.

    Wheal test

    Raised, beetlike efflorescence with a red areola, as the expression of an acute edema of the skin.

    Wheal test method: If a wheal applied intracutaneously with 0.2 ml of isotonic saline solution is no longer evident after 40 to 45 minutes, the patient has a propensity to develop edema. Disappearance of the wheals within 3 to 30 minutes indicates pronounced edema tendency.

    DEFINITIONS

    • Neural therapy: Treatment of a disease via the autonomic nervous system.
    • Autonomic nervous system: A functional unity which includes the entire conditional-reflectorally functioning neuro-humoral system of regulation.
    • The autonomic nervous system includes:
      • The sympathetic nervous system
      • The parasympathetic nervous system
    • Basic autonomic neural system: An interstitial (i.e., located in intermediate tissue), soft connecting tissue which fills the interstices between organs. It is composed of cells, nerves, capillaries, and the extracellular liquid space. This system performs communicative functions required to provide connection between each cell of the body and every other cell.
    • Segment therapy: Therapy administered in a segment via Head’s zones. Deeper-lying organs are accessed via dermato-visceral reflex paths (as defined by Pischinger).
    • Focal therapy: If no success is achieved after repeated local or segment therapy, it may be assumed that a focal disorder is responsible for the complaint. It is then necessary to search for the responsible focus.
    • Local therapy: Direct administration of neural therapeutic agents which enables long-term freedom or relief from symptoms.
    • Procaine: p-aminobenzoyl diethylaminoethanol hydrochloride; the most frequently used local anesthetic; weak in its effects, non-toxic, and not harmful to human tissues.
    • Local anesthetic: An agent which, when locally administered, reversibly eliminates the excitability and conductivity of nerves or their endings. The area involved then becomes insensitive to pain.
    • Local anesthesia: Insensitiveness to pain in a locally restricted area of the body.
  • Lymphomyosot minimizes the risks associated with diabetic neuropathy

    Activates the lymphatic system

    The efficacy of Lymphomyosot for the treatment and prevention of lymphatic disorders has been demonstrated in numerous studies¹–⁵.

    Extremely well tolerated

    In a study of 3,512 patients, including 1,124 (32%) children under 10 years of age, 99.8% assessed Lymphomyosot therapy as “very well tolerated” throughout the course of treatment¹.

    3 different dosage forms

    • Drops: 15 drops 3 times per day
    • Tablets: 3 tablets 3 times per day
    • Ampoules: 1 ampoule 1 to 3 times per week

    As a standard for comparison, 10 infusions with 600 mg of α-lipoic acid over 8 months improved tactile sensitivity among study patients by only Ø +0.9. However, a combination therapy with Lymphomyosot (15 drops twice daily for 8 months) and α-lipoic acid (10 infusions with 600 mg of α-lipoic acid over 8 months) improved tactile sensitivity by Ø +3.25⁵.

    • Neural nutrient insufficiency
    • Diminished tactile sensitivity
    • Defence reaction absent
    • Risk, imbalance, damage
    • Amputation
    • Gangrene
    • Diabetes
    • Diabetic foot
    • Inflammation
    • Malfunction/glycosylation of the matrix
    • Peri-neural oedema

    Reduction of oedema

    50 patients diagnosed with diabetic neuropathy were administered 15 drops of Lymphomyosot twice daily for 8 months. At the end of the treatment period, lymphoedema and tactile sensitivity had profoundly improved⁵.

    Improvement of tactile sensitivity

    Minimizes the risks associated with diabetic neuropathy

    • Improved matrix metabolism
    • Improved tactile sensitivity
    • Eliminated pain in 75% of patients
    • Lymphatic disorders
    • Recurrent infections
    • Detoxification and drainage

    Lymphomyosot – recommended for

    • Lymphhoedema (i.e. for promoting postmammectomy drainage)
    • A compromised defence system (i.e. for treating recurrent and acute infections, and inflammatory disorders such as tonsillitis or lymphangitis)
    • Tonsillar hypertrophy
    • Lymphadenitis
    • Systemic toxicities (i.e. for treating chronic diseases or amalgam-related disorders)

    Composition:

    • Drops: 100 g cont.: Myosotis arvensis D3, Veronica officinalis D3, Teucrium scorodonia D3, Pinus silvestris D 4, Gentiana lutea D 5, Equisetum hyemale D4, Sarsaparilla D6, Scrophularia nodosa D3, Juglans regia D3, Calcium phosphoricum D12, Natrium sulfuricum D4, Fumaria officinalis D4, Levothyroxinum D12, Araneus diadematus D6 5 g each; Geranium robertianum D4, Nasturtium officinale D4, Ferrum jodatum D12 10 g each. Contains 35 vol.-% alcohol.
    • Tablets: 1 tablet cont.: Myosotisarvensis D3, Veronica officinalis D3, Teucrium scorodonia D3, Pinus silvestris D4, Gentiana lutea D5, Equisetum hyemale ex herba rec. D4, Sarsaparilla D6, Scrophularia nodosa D3, Juglans regia D3, Calcium phosphoricum D12, Natrium sulfuricum D4, Fumaria officinalis D4, Levothyroxinum D12, Araneus diadematus D6 5 g each; Geranium robertianum D4, Nasturtium officinale D4, Ferrum jodatum D12 10 g each.
    • Injection solution: 1.1 ml cont.: Myosotis arvensis D3, Veronica officinalis D3, Teucrium scorodonia D3, Pinus silvestris D4, Gentiana lutea D5, Equisetum hyemale D4, Sarsaparilla D6, Scrophularia nodosa D3, Juglans regia D3, Calcium phosphoricum D12, Natrium sulfuricum D4, Fumaria officinalis D4, Levothyroxinum D12, Araneus diadematus D6 0.55 µl each; Geranium robertianum D4, Nasturtium officinale D4, Ferrum jodatum D12 1.1 µl each.

    Indications: Status lymphaticus (tendency to hyperdevelopment of the lymphatic organs; tendency to development of oedemas and infections); glandular swelling; tonsillar hypertrophy; chronic tonsillitis.
    Contraindications: In case of thyroid disorders, this preparation may not be administered without prior approval from a physician.
    Side effects: None known.
    Interactions with other medication: None known.
    Dosage: Drops: In general, 15-20 drops 3 times daily. Tablets: In general, 3 tablets to be dissolved in the mouth 3 times daily. Injection solution: In acute disorders daily, otherwise 3-1 times weekly 1 ampoule i.m., s.c., i.d.
    Package sizes: Drops: Drop bottles containing 30 and 100 ml. Tablets: Packs containing 50 and 250 tablets. Injection solution: Packs containing 10, 50 and 100 ampoules of 1.1 ml.
    Revised: April 2001.

    References

    1. Zenner S, Metelmann H: Therapeutic Use of Lymphomyosot® – Results of a Multicentre Use Observation Study on 3,512 Patients. Biological Therapy 1990, Vol Vlll No. 3.: 49–53,67–72, and Vol Vlll, No. 4: 79–84, 94
    2. Küstermann K, Weiser M: Treatment of a Lymphatic Disease with Homoeopathic Therapy. Biologische Medizin 1997; Vol 26 No. 3: 110–114
    3. Rinneberg A-L: Lymphomyosot®: The Therapy of Tonsillitis and Prophylaxis against its Recurrence. Biological Therapy 1991; Vol IX No. 1: 111–114
    4. Riley D, White S: A Biotherapeutic Approach to the Treatment of Inflammatory Disorders: A Drug Monitoring Trial. Biological Therapy 1992; Vol. X No. 3: 267–271
    5. Dietz R: Possibilities of Lymph Therapy with Diabetic Polyneuropathy. Biologische Medizin 2000; Vol 29 No. 1: 4–9

  • Common Disorders of the Ear, Nose, and Throat: A Clinical Update

    By Joan Lewis, MD
    Otorhinolaryngologist

    Introduction

    Disorders of the ear, nose, and throat (ENT) are the cause of many patient visits to a primary care physician. Some of the common ENT disorders include acute and recurrent otitis media (OM); acute, chronic, and recurrent tonsillitis; and allergic and recurrent rhinitis and chronic rhinosinusitis (CRS). However, the common cold remains one of the most frequent upper respiratory tract infections (URIs). Approximately half of the cases of colds in children can be attributed to a wide variety of up to 200 different viruses that are seasonally active, such as rhinoviruses in the early fall, spring, and summer. Other viruses that might cause URIs include coronavirus, parainfluenza virus, adenovirus, enterovirus, and respiratory syncytial virus.¹

    The subsequent development of recurrent sinusitis²–³ and OM⁴ commonly has been related to viral URIs that last longer than a week. A child can be expected to have 6 to 10 colds annually, whereas adolescents may have only 2 to 4 colds per year. In developing countries, URIs tend to be more severe, such as pneumonia and influenza, with a higher risk of complications. Therefore, URIs can be a leading cause of death for children younger than 5 years.⁵

    An increased understanding of the pharmacoeconomic incidence, relevance of antibiotic resistance, physician involvement, and anatomical and physiological features of each of the common ENT disorders will improve clinical outcomes. An integrative medical approach that uses complementary and alternative therapies, such as antihomotoxic medications, in addition to mainstream medical therapies is a therapeutic strategy that shows much promise in reducing the current disease burden and preventing further recurrences.

    Pharmacoeconomic Incidence

    The annual cost of time lost from school for adolescents and from work for adults because of URIs is substantial and is estimated to be as high as $15 billion in direct treatment costs by practitioners, with more than half of that amount being for ambulatory care centers in hospitals. The indirect cost of wages from URIs is estimated at $9 billion.⁶

    The over‑the‑counter cough and cold remedy market was identified as being the “most competitive category in North America,” with sinusitis showing the most potential growth. Figures extrapolated from a survey of 4,000 US residents suggested that a total economic burden of $40 billion, including income lost from time off for these occurrences, was related to noninfluenza viral URIs alone.

    Antibiotic Resistance

    In 2007, prudent antibiotic use was not correlated with appropriate knowledge of microbial resistance;⁷ thus, the reduction of unnecessary antibiotics as treatment options for the virally associated common cold was identified in 2008 as a public health priority.⁸

    Recent public opinion polls show an increased understanding of the relationship between the development of resistant bacterial strains and inappropriate antibiotic use and also report a significantly higher level of trust in physicians who did not prescribe antibiotics for the common cold.⁹ However, 45% of respondents in the United States in 2008 and 41% of a population in Belgium in 2001 still did not understand the lack of efficacy of antibiotics in treating viral illnesses.¹⁰ These data suggest that there is still a considerable opportunity to better educate patients and health care providers.

    Environmental Impact

    In the pediatric population, the close proximity of children in day‑care centers contributes to the transmission of respiratory tract disease.¹¹ Childhood exposure to common environmental pollutants, such as firsthand or secondhand smoke, and common household allergens, such as aerosolized cleaning products, in persons with a genetic predisposition might be associated with later development of asthma and allergic conditions through inappropriate sensitization.¹² Furthermore, asthmatic children have URIs more frequently than their nonasthmatic classmates. The polycyclic aromatic hydrocarbons present in diesel exhaust particles have recently been shown to stimulate the release of interleukin (IL)‑4, IL‑8, and histamine from basophil cells,¹³ suggesting that other common environmental pollutants also can play a role in the development of asthma and allergic rhinitis.

    Physician Involvement

    Most persons with ENT disorders visit their health care practitioners early in the disease process because the associated signs and symptoms are readily apparent to both the patient and practitioner and frequently affect activities of daily living. The mechanical and physical appearances of structures (e.g., teeth, palate, gingiva, and tongue) indicate a variety of physiological states and can be used diagnostically with a minimal investment of time. For example, fasciculations of the tongue might indicate neural disorders; a glossy tongue is associated with nutritional deficiencies, such as a deficiency in vitamin B12. Dental caries or loss correlates with impaired immune systems, smoking or tobacco use or exposure,¹⁴ and poor nutritional status. Xerostomias are linked to poor hygiene, and temporomandibular joint disorders can be attributed to trauma or articular disorders.¹⁵

    Relevant Anatomical and Physiological Features

    Lymphatic tissue in the Waldeyer ring is designed to protect the body from pathogens and toxins encountered in this vulnerable area; therefore, it is strategically placed to protect critical respiratory and digestive functions. It is the first protective barrier encountered by orally ingested and inhaled toxins, viruses, and bacteria. An interaction with the body’s lymphatic tissues provokes a reaction that includes copious nasal discharge, sneezing, coughing, and mucosal engorgement as a mechanism to remove the offending substance. The resultant reaction, with its associated signs and symptoms, is diagnosed as the common cold or rhinitis. Further progression to include fever and exhaustion, and the presence of clusters of similar infections in the community and a documented influenza virus infection, would lead to a diagnosis of the flu.

    Treatment for these uncomfortable reactions is largely symptomatic.


    Pathological Conditions

    A short review of the relevant pathological features of each of the common ENT disorders is included to provide further insight into potential therapeutic strategies.

    Otitis Media

    Acute OM
    Acute OM is the most frequent ailment encountered by pediatricians. Persistent middle ear effusion from a failure of the mucus and microbial and immune system debris in the middle ear to drain via the Eustachian tube to the pharynx is associated with recurrent OM.¹⁶ Implicated factors include functional obstruction of the Eustachian tube, anatomical differences in the infant’s Eustachian tube, and a more horizontal position when bottle feeding an infant in a supine position, favoring a retrograde flow of milk. Furthermore, passive smoke environments impair normal ciliary movement that sweeps away debris, and immune system disorders are associated with increased mucus production.

    Recurrent OM
    Preexisting antibiotic treatment is associated with an increased rate of recurrent OM in young children, supporting the hygiene hypothesis, in which interruption of a normal inflammatory response during childhood leads to an imbalance in Th1/Th2 cell regulation, predisposing a child toward allergy.¹⁷ Novel otopathogens can be cultured in those with recurrent OM after a month‑long course of antibiotics for acute OM.¹⁸ Long‑term morbidity, with recurrent OM occurring before the age of 3 years, might affect the child’s subsequent decreased comprehension when reading.¹⁹

    Bioregulatory Treatment
    For acute OM, use the basic/symptomatic approach as follows: prescribe Belladonna-Homaccord (8–10 drops twice daily) and Traumeel (8–10 drops or 1 ampoule warmed and instilled into the affected ear twice daily). If resolution does not occur within a reasonable time, individualize therapy:

    • With confirmed bacterial etiology and significant inflammation, prescribe Echinacea compositum: 1 tablet every 30–60 minutes up to 12 tablets per day for acute conditions; for chronic conditions, 1 tablet dissolved in the mouth three times daily. Injectable route (IM, SC, ID, or IV) 1–3 times per week may be used if within regulatory framework.†
    • With confirmed viral etiology, prescribe Engystol: 1 tablet three times daily or 1 ampoule daily (injectable routes as above for acute situations).
    • For marked restlessness, fever, and agitation, prescribe Viburcol suppositories: adults, 1 suppository 2–3 times daily; infants under 6 months, half a suppository up to one per day.

    If signs and symptoms persist, consider the 3‑pillar regulation approach (detoxification and drainage; immunomodulation; cell and organ support).† During latent phases, Mucosa compositumCoenzyme compositum, Ubichinon compositum) supports cells and organs; Traumeel for immunomodulation; and the Detox‑Kit (comprising Lymphomyosot, Nux vomica-Homaccord, and Berberis-Homaccord) for detoxification and drainage. Persistent effusion may require referral for myringotomy.

    Tonsillitis

    Acute Tonsillitis
    Tonsils are antigen‑presenting lymphatic tissue in the Waldeyer ring, mounting an appropriate B‑cell response. Acute tonsillitis presents as erythematous, swollen tonsils with stertorous breathing. Hypertrophied tonsils can cause sleep disorders and daytime inattentiveness in children. Microbiological evaluation (culture or rapid antigen tests) is required to exclude streptococcal pharyngitis, which necessitates antibiotics to prevent cardiovascular or renal complications.²⁰

    Chronic Tonsillitis
    Generally bacterial in etiology and more prevalent in adults. Crypts containing pus can form; surgical excision is controversial due to postoperative pharyngitis despite no visible recurrent infection. Post‑tonsillectomy changes in oral flora suggest the chronically infected tonsil may harbor anaerobic bacteria, and removal may restore normal flora.²¹

    Recurrent Tonsillitis
    In children, recurrent tonsillitis differs from adult chronic forms by higher antigen presence in acute stages. If peritonsillar abscess occurs, immediate tonsillectomy may be first‑line.²² Antigen presentation and B‑cell function remain intact; if possible, avoid tonsillectomy to preserve natural killer cell maturation.

    Bioregulatory Treatment
    For acute tonsillitis: prescribe Angin-Heel (initial: 1 tablet every 15 minutes for 2 hours; then 1 tablet three times daily), Vinceel spray (once daily), and Mercurius-Heel (1 tablet three times daily). If unresponsive:

    • Bacterial etiology: Echinacea compositum as above.
    • †Regulation approach: use detoxification, immunomodulation, and organ support as outlined for OM.

    References

    1. Common cold viruses and URIs; rate in children and adults.
    2. Recurrent sinusitis etiology overview.
    3. Recurrent sinusitis pathophysiology.
    4. Otitis media linkage to viral URI.
    5. URI mortality in children <5 years.
    6. Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med. 1985;78(6B):45‑51.
    7. McNulty CA, et al. Public’s knowledge and attitudes to antibiotic use. J Antimicrob Chemother. 2007;59(4):727‑738.
    8. Earnshaw S, et al. European Antibiotic Awareness Day survey. Euro Surveill. 2009;14(30):19280.
    9. Andre M, et al. Public knowledge of antibiotic use in Sweden. J Antimicrob Chemother. 2010;65(6):1292‑1296.
    10. Edgar T, Boyd SD, Palame MJ. Sustainability for behaviour change against antibiotic resistance. J Antimicrob Chemother. 2009;63(2):230‑237.
    11. Fleming DW, et al. Day‑care attendance and pediatric URIs. Pediatrics. 1987;79(1):55‑60.
    12. Arshad SH. Indoor allergen exposure and allergy development. Curr Allergy Asthma Rep. 2010;10(1):49‑55.
    13. Lubitz S, et al. Diesel exhaust proallergic effects. Environ Toxicol. 2010;25(2):188‑197.
    14. Tanaka K, et al. Smoking and tooth loss in Japanese women. Ann Epidemiol. 2005;15(5):358‑364.
    15. McNeill RA. Bacteria in ear and nasopharynx in acute OM. J Laryngol Otol. 1962;76:617‑622.
    16. Emerick KS, Cunningham MJ. Tubal tonsil hypertrophy after adenoidectomy. Arch Otolaryngol Head Neck Surg. 2006;132(2):153‑156.
    17. Mattila PS. Amoxicillin and recurrent OM in young children. J Pediatr. 2010;156(1):163.
    18. Kerschner JE, et al. Otitis media risk factor knowledge. Int J Pediatr Otorhinolaryngol. 2005;69(1):49‑56.
    19. Luotonen M, et al. Recurrent OM and linguistic skills. Pediatr Infect Dis J. 1996;15(10):854‑858.
    20. Bonsignori F, et al. Upper respiratory tract infections in children. Int J Immunopathol Pharmacol. 2010;23(suppl 1):16‑19.
    21. Burton MJ, Glasziou PP. Tonsillectomy vs non‑surgical for chronic/recurrent tonsillitis. Cochrane Database Syst Rev. 2009;(1):CD001802.
    22. Page C, et al. Immediate tonsillectomy for peritonsillar abscess. J Laryngol Otol. 2010:1‑6.

    †The 3‑pillar regulation approach comprises detoxification and drainage; immunomodulation; and cell and organ support.

  • Prevention of cadmium-induced toxicity in liver-derived cells by the combination preparation Hepeel®

    Rolf Gebhardt*

    Institute of Biochemistry, Medical Faculty, University of Leipzig, Johannisallee 30, 04103 Leipzig, Germany


    ARTICLE INFO

    Article history:

    • Received 21 May 2008
    • Received in revised form 11 December 2008
    • Accepted 18 January 2009
    • Available online 31 January 2009

    Keywords:

    • Antioxidants
    • Apoptosis
    • Cadmium
    • Cytochrome C
    • Hepatoprotection
    • Plant tinctures

    ABSTRACT

    Cadmium is a heavy metal of considerable environmental concern that causes liver damage. This study examined the possible prevention of cadmium toxicity in human HepG2 cells and primary rat hepatocytes by Hepeel®, a combination preparation of tinctures from seven different plants. Hepeel® prevented cadmium chloride (CdCl₂)-induced cell death in both HepG2 cells and hepatocytes, and also reduced the loss of glutathione, lipid peroxidation, nuclear fragmentation, caspase activation and release of mitochondrial cytochrome C. To compare their relative efficacy, the seven constituent plant tinctures of Hepeel® were also separately tested. The tinctures China and Nux moschata, which exert solely anti‑oxidative effects, failed to reduce cytotoxicity, and only protected against loss of glutathione and lipid peroxidation. In contrast, the tinctures Carduus marianus and Chelidonium, demonstrated anti‑apoptotic effects, and protected HepG2 cells and primary hepatocytes against CdCl₂-induced cell death. These results demonstrate how the effectiveness of Hepeel® is determined by the synergistic features of its constituent tinctures. Furthermore, we conclude that cadmium toxicity in the liver is mainly due to stimulation of the intrinsic apoptotic pathway, but may be intensified by increased oxidative stress.

    © 2009 Elsevier B.V. All rights reserved.


    1. Introduction

    Environmental exposure to fluctuating concentrations of heavy metals poses an enormous challenge for biological organisms. Toxic metals cause a vast array of adverse effects, including neurotoxicity, hepatotoxicity and carcinogenicity (Waalkes et al., 2000; Godt et al., 2006). Due to the global dispersion of heavy metals and their extensive use in modern society, some human exposure to toxic metals is inevitable. This ongoing prevalence of metal exposure necessitates protective measures at the environmental, social and individual level.

    Cadmium is one of the most common toxic heavy metals, due to its primary accumulation in the liver and kidney (Godt et al., 2006). Cadmium causes hepatic, renal, skeletal, respiratory, and vascular disorders in humans (Nordberg, 1992; Waalkes et al., 2000), and it may also affect Leydig cells of the testes and hepatocytes and stellate cells of the liver (Koizumi et al., 1992; Dudley and Klaassen, 1984; Fariss, 1991; Souza et al., 2004a,b). Furthermore, cadmium is a potent carcinogen (Godt et al., 2006).

    There is growing evidence that the oxidative stress (Sarkar et al., 1995) via reactive oxygen species (ROS) generation and mitochondrial damage are among the basic mechanisms of cadmium toxicity (Sarkar et al., 1995).

    The combination preparation Hepeel® is frequently used to stimulate liver function and improve antioxidant function in acute and chronic diseases, such as cholangitis and cholecystitis (Gebhardt, 2003). Hepeel® also demonstrates several other protective features, such as induction of glutathione-S-transferase activity (Gebhardt, 2003). These findings prompted the present investigation of the hepatoprotective potential of Hepeel®, and its seven constituent plant tinctures, against cadmium-induced hepatocellular damage. To thoroughly examine this, and to provide comparative experimental data for two different cell types, we used the human hepatoblastoma cell line HepG2 and primary rat hepatocytes. Exposure to Hepeel® largely prevented cell death, and oxidative and apoptotic pathomechanisms were differentially affected by the constituent tinctures. The combined anti-oxidative and anti-apoptotic properties of Hepeel® and its constituent tinctures support its overall protective effect against cadmium-induced toxicity in liver cells.

    2. Materials and methods

    2.1 Materials

    Hepeel® tinctures were prepared from seven different plants, according to procedures 3 and 4 of the German Homeopathic Pharmacopoeia (HAB, 2000), and were provided by the Biologische Heilmittel Heel GmbH (Baden-Baden, Germany). The following seven constituent tinctures were used: (1) Chelidonium majus, prepared from Chelidonium majus L. (Ch-B 007009, 10⁻² dilution), (2) Carduus marianus, prepared from Silybum marianum L. (Ch-B 007034, 10⁻² dilution), (3) Verratrum album L. (Ch-B 007050, 10⁻³ dilution), (4) Colocynthis, prepared from Citrullus colocynthis L. (Ch-B 007058, 10⁻³ dilution), (5) Lycopodium, prepared from Lycopodium clavatum L. (Ch-B 007001, 10⁻³ dilution), (6) Nux moschata, prepared from Myristica fragrans Houtt (Ch-B 007026, 10⁻³ dilution), and (7) China, prepared from Cinchona pubescens, Vahl (Ch-B 007018, 10⁻³ dilution). Hepeel® is a combination of all tinctures at the dilutions given above, with the addition of Phosphorus, a 10⁻³ dilution of yellow phosphorus. Hepeel® was supplied in sterile ampoules by Biologische Heilmittel Heel GmbH. The relative volume composition of 1:1 mL Hepeel® injection solution is: Chelidonium majus, 10⁻³ dilution) 1.1 μL; Carduus marianus (Silybum marianum, 10⁻³ dilution) 0.55 μL; Verratrum album, 10⁻² dilution) 2.2 μL; Colocynthis (Citrullus colocynthis, 10⁻³ dilution) 3.3 μL; Lycopodium clavatum, 10⁻² dilution) 1.1 μL; Nux moschata (Myristica fragrans, 10⁻³ dilution) 1.1 μL; China (Cinchona pubescens, 10⁻³ dilution) 1.1 μL and Phosphorus (white phosphorus 0515.41).

    Dichlorodiphenyltrichloroethane (DDT) was purchased from Sigma (Daisenhofen, Germany). All other chemicals were from Roche Diagnostics (Mannheim, Germany), Merck (Darmstadt, Germany), Roth (Karlsruhe, Germany) or Sigma (Daisenhofen, Germany). Cell culture plates with tissue culture filter inserts were from Techno Plastic Products AG (Trasadingen, Switzerland).

    2.2 Culture of HepG2 cells

    HepG2 hepatoblastoma cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, Eggenstein, Germany) supplemented with 2 mM glutamine, 10% fetal calf serum, 40 U/mL streptomycin and 50 U/mL penicillin, as previously described (Gebhardt, 1997). Cells were passed weekly, when confluent. Cell stocks (passage ≤31 till 40) were kept frozen in liquid nitrogen. Frozen cells were thawed, cultured for one week, and passed at least once before use. Confluent HepG2 cell cultures were used for all experiments.

    2.3 Preparation and culture of rat hepatocytes

    Sprague-Dawley rats were bred and maintained at the Medizinisch-Experimentelles Zentrum at the University of Leipzig, according to local ethical rules for animal care. They were kept on normal maintenance diet V1534 (Sniff, Soest, Germany) and tap water, ad libitum. Primary hepatocyte cultures were prepared by the livers of male rats (200–310 g) with collagenase perfusion, as previously described (Gebhardt, 1997). Cells were cultivated in Williams medium E (Lonza, Verviers, Belgium) on collagen-coated plastic plates, at a uniform cell density of 125,000 cells/cm². During the first 2 h, culture medium was supplemented with 10% fetal calf serum, and culture medium was used thereafter. The medium volume was maintained at 100 μL/cm² of plating area. Additional details of cell culture have been reported elsewhere (Gebhardt, 1997; Gebhardt et al., 1994). For toxicity experiments, incubation in various agents usually started 2 h after plating.

    2.4 Induced toxicity with cadmium chloride

    The nominal concentration of CdCl₂-induced cytotoxic effects was different for each cell type. For HepG2 cells, culture medium was supplemented with concentrations ranging from 3 to 8 μM. For primary rat hepatocytes, concentrations ranged from 2 to 6 μM. The highest CdCl₂ concentrations caused the greatest cell death in each cell type. In HepG2 cells, 8 μM CdCl₂ caused about 52% cell death, within 30 h of incubation, in hepatocytes, 6 μM CdCl₂ caused 72% cell death within 24 h of cultivation.

    2.5 Preparation of Hepeel® tinctures

    To prepare a working dilution of each tested compound, one part Hepeel® or tincture was mixed with 5 parts v/v of serum-free Williams Medium E, and gently shaken for 20 min at room temperature. This working solution of effective 0.1 dilution was used for further dilutions with Williams Medium E as specified in figure legends. Appropriate controls replaced each tincture or Hepeel® with equal volumes of ethanol.

    2.6 Determination of cytotoxicity

    Cytotoxicity of the tested compounds was determined using the colorimetric MTT-assay (MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), as previously described (Gebhardt, 1997).

    2.7 Determination of lipid peroxidation and ROS production

    Malondialdehyde (MDA) measurements were used to quantify lipid peroxidation (Gebhardt, 1997). HepG2 cells or rat hepatocytes seeded on 60 mm petri dishes were incubated with or without CdCl₂ (3 or 4 μM) for 60 min after 30 h and 24 h of cultivation, respectively. In order to enhance oxidative stress, some plates were simultaneously exposed to t‑butyl hydroperoxide (t‑BHP; final concentration 1.5 mM). Thereafter, cells were washed with 0.9% NaCl, resuspended, and scraped into 1 mL of 50 mM potassium phosphate buffer (pH 7.4), then homogenised by sonication for 10 s (15 μs maximal sonpower, Sonipuls HD 2200, Bandelin electronic, Berlin, Germany). MDA was determined by thiobarbituric acid (TBA) assay (Esterbauer and Cheeseman, 1990; Gebhardt, 1997). The protein content of homogenates was measured following the procedure of Lowry et al. (1951).

    Measurement of intracellular ROS was accomplished by using the DCFH assay (Wang and Joseph, 1999). HepG2 cells or rat hepatocytes cultivated on collagen-coated 95-well black flat bottom plates were washed 3 times with Krebs‑Ringer‑HEPES (KRH) solution pH 7.2 (Pavlica and Gebhardt, 2005). Cells were preloaded with 0.1 mM DCFH in either DMEM (HepG2 cells) or Williams Medium E (rat hepatocytes) for 30 min, then washed 3 times with KRH buffer. Cells were then treated simultaneously with CdCl₂ (3 μM) and the test compound diluted 1:10 with different starting dilutions (indicated in Table 1) for an additional 30 min. Fluorescence (485/520 nm, excitation 485/emission 520 nm, microplate reader, TECAN) was recorded for up to 30 min, while temperature was maintained at 37 °C. Percentage increase in fluorescence units/well was calculated by the formula: F₃₀/F₀ × 100, where F₃₀ = fluorescence at time 30 min, and F₀ = fluorescence at time 0 min (Pavlica and Gebhardt, 2005).

    2.8 Determination of cellular glutathione content

    To measure cellular glutathione (GSH) content, cells were cultured in 6-well plates for 30 h (HepG2 cells) or 24 h (primary rat hepatocytes). Test compounds were added 2 h after plating, along with the first change of medium. At the end of the incubation period, cells were washed and scraped into HEPES buffered isotonic medium as previously described (Pavlica and Gebhardt, 2005). Determination of GSH content was performed according to the method of Gebhardt and Faustel (1997).

    2.9 Detection of apoptotic nuclei with DAPI

    The blue nuclear dye DAPI (4′,6-Diamidino-2-phenylindole) was dissolved in methanol at 5 μg/mL and stored as stock solution. Cells were washed twice in potassium phosphate buffer (PBS) and fixed with ice-cold methanol. Thereafter, a working solution of DAPI (1 μg/mL) in methanol was added, and cell nuclei were stained for 15 min at 37 °C. Destaining was achieved by replacing methanol with pure methanol, followed by two rounds of washing with PBS.

    2.10 Determination of caspase activity

    Measurement of caspase-3 activity was based on the cleavage of a colorimetric substrate determined by the increase in absorbance at 405 nm. The assay was performed according to the instructions of the manufacturer (caspase-3 activity assay kit; Oncogene, Bad Soden, Germany) and adapted for HepG2 cells as described by Ochiai et al. (2004). Recombinant caspase-3 was used for assay calibration.

    2.11 Preparation of cellular fractions and Western blot analysis

    To measure cytochrome C release, cellular extracts were prepared by lysing cells in 10 mM Tris-buffer (pH 7.4) containing 2 mM EDTA, 1 μM pepstatin, 1 mM PMSF, leupeptin, 100 μM PMSF (phenylmethylsulfonyl fluoride), and 250 mM sucrose. Cells were homogenized by repeated passage through a 26-gauge needle, and were centrifuged at 14,000 × g for 10 min at 4 °C. Cytosolic supernatants and pellets containing mitochondria were collected and analyzed for spectral concentrations of mitochondrial protein, then used for Western blot analysis as previously described (Haupt et al., 2000). Cytochrome C was detected using a cytochrome C (Ab-8) antibody (sc-13156, Santa Cruz Biotechnology Inc., Heidelberg, Germany) followed by alkaline phosphatase-conjugated secondary antibody.

    2.12 Statistical evaluation

    Data were analysed for significance with a Student’s t-test for comparisons between two groups. Data are presented as mean ± standard deviation (SD) of three to four measures, except when stated otherwise.

    3. Results

    3.1 Cytotoxicity of cadmium chloride on hepatocellular populations

    The cytotoxic effect of CdCl₂ on HepG2 cells was concentration- and time-dependent. Within the first 24 h of exposure, HepG2 cells tolerated up to 5 μM CdCl₂, but quickly died at higher concentrations (Fig. 1). At 7 μM CdCl₂, almost all cells were dead or had detached from the substrate. At 5 μM CdCl₂ or below, no visible alterations in cell morphology and nuclei were detectable after 24 h (data not shown). However, deterioration was seen at 5 μM CdCl₂ when cultivation was continued for another 6 h (Fig. 1). At that time, cadmium-induced cytotoxicity was already apparent at lower concentrations. The first signs of cytotoxic influence were detected above 2 μM, and almost all cells died at a concentration of 5 μM, as determined by MTT reduction to less than 10% of controls. The EC₅₀-value for CdCl₂-induced cytotoxicity in HepG2 cells was determined to be 5.9 μM after 24 h, and 2.8 μM after 30 h of cultivation.

    Rat hepatocytes were even more sensitive to cadmium, and cytotoxicity was more prominent than in HepG2 cells, at all culture times. At 24 h after addition of CdCl₂, MTT reduction was already decreased in a concentration-dependent manner, above 2 μM doses (Fig. 2). At 6 μM, absorbance was reduced by approximately 70%. The EC₅₀-value for CdCl₂-induced toxicity was 3.7 μM. After 30 h, cell detachment in the MTT assay had further dropped, and were lower than those of HepG2 cells at all concentrations of cadmium (data not shown). Therefore, all subsequent measurements of cell viability were performed in HepG2 cells at 30 h of cultivation, and in rat hepatocytes at 24 h of cultivation.

    3.2 Protection against cadmium cytotoxicity by Hepeel® and constituent tinctures

    In the presence of Hepeel®, cadmium cytotoxicity was reduced in both cell types. In HepG2 cells at 30 h of culture, Hepeel® application resulted in the gradual increase of viability from 32% (control) to 53%, as dilutions changed from 10⁻³ to 10⁻¹ (Fig. 3A). At the 10⁻² dilution, there was significant enhancement of viability (P < 0.01).

    Among the constituent tinctures, only Carduus marianus and Chelidonium, were effective in reducing cadmium cytotoxicity (Table 1). Within the range of 10⁻⁵ to 10⁻³ dilutions, Carduus marianus caused increased cell viability in a concentration-dependent manner, to values between 60 and 70% (Fig. 3B). Chelidonium application resulted in maximal values slightly above 60% (Fig. 3C). Also, the cell sensitivity was slightly higher with Carduus marianus, and significant differences were seen starting at the 2.5 × 10⁻⁴ dilution, whereas with Chelidonium significant differences were not apparent until the more concentrated dilutions of 10⁻⁴ and lower.

    Similar results were obtained with rat hepatocytes after 24 h of cultivation. The 10⁻³ dilution of Hepeel® increased viability from 68% to almost 88%. At the same 10⁻³ dilution, Carduus marianus reached 95% and Chelidonium increased 87% viability (Table 1). As for HepG2 cells, the other constituents of Hepeel® did not reduce cytotoxicity (Table 1).

    3.3 Cadmium-induced lipid peroxidation and ROS production

    Exposure of HepG2 cells to CdCl₂ for 24 h did not change the rate of lipid peroxidation, as evidenced by the unchanged cellular production of malondialdehyde (MDA) compared to control measures (Table 2). However, when challenged with 1.5 mM t‑BHP, HepG2 cells exposed to 3 μM CdCl₂ responded with a 2.1-fold increase, and those exposed to 4 μM responded with a 2.3-fold increase of MDA, compared to control cells not exposed to cadmium.

    Likewise, ROS production of HepG2 cells detected by DCFH fluorescence was stimulated by CdCl₂ only in the presence of t‑BHP (Table 2). The relative increase in ROS production was comparable to that for lipid peroxidation.

    As shown in Table 3, Hepeel® significantly reduced t‑BHP-induced MDA production in both untreated HepG2 (control) cells and HepG2 cells exposed to CdCl₂ for 24 h. Among all tinctures, Carduus marianus was the most effective (Table 3). Dilutions were almost as broad.

    Likewise, ROS production of HepG2 cells was reduced in a pattern similar to that of MDA measures: Hepeel® (31%), Carduus marianus (36%), China (18%), and Nux moschata (16%). All other tinctures were ineffective at reducing the CdCl₂-induced MDA production (data not shown).

    The results for rat hepatocytes were different. In these cells, CdCl₂ led to an increase of MDA production of 55%, and an increase in ROS production of 32%, compared to control hepatocytes exposed to cadmium. However, as in HepG2 cells, the sensitivity to t-BHP in the presence of cadmium was also increased approximately 2-fold, from 155% to 302% for MDA, and from 132% to 273% for ROS. The following agents significantly counteracted the impact of CdCl₂, as apparent via the following reduction in MDA measures: Hepeel® (31%), Carduus marianus (36%), China (18%), and Nux moschata (16%). All other tinctures were ineffective at reducing the CdCl₂-induced MDA production (data not shown).

    3.4 Cadmium-induced loss of GSH

    A moderate drop in cellular GSH (19 ± 5%) was observed in HepG2 cells in response to exposure to CdCl₂ at a concentration of 3 μM (Table 4). This value is in accordance with an EC₅₀-value of approximately 4.5 μM. This loss was considerably enhanced (55 ± 4%) when cells were additionally exposed to t‑BHP. Only Hepeel® and the tinctures Carduus marianus, China and Nux moschata were able to significantly counteract the influence of CdCl₂, with or without additional t‑BHP (Table 4). When used alone, Hepeel® and Carduus marianus were able to completely restore cellular GSH content.

    3.5 Cadmium-induced apoptosis

    Cadmium toxicity via apoptosis was measured by DAPI-staining in two different ways; counting of fragmented nuclei and monitoring of cell death. Within 30 h of 3 or 4 μM CdCl₂ exposure, apoptotic fragmentation in HepG2 cell nuclei was apparent after DAPI staining, and total cell numbers were decreased (Fig. 4). Specifically, the percentage of apoptotic nuclei increased from less than 0.1% (controls) to about 8% in the presence of 3 μM CdCl₂ (Table 5). At earlier time points, such as 24 h, the proportion of fragmented nuclei was lower than at 30 h.

    Addition of Hepeel® to the culture medium considerably reduced the apoptotic response at all concentrations of CdCl₂ in HepG2 cells and hepatocytes (Table 5). This influence was particularly pronounced in hepatocytes exposed to 4 μM CdCl₂, wherein the proportion of apoptotic nuclei was diminished from 42% to 4% (Table 5). A similar but less pronounced effect of Hepeel® could be observed in the presence of 5 μM CdCl₂ (cf. Fig. 5D).

    Similar to the results seen in the MTT assays, the co-application of either Carduus marianus or Chelidonium with CdCl₂ effectively reduced the number of apoptotic nuclei, and enhanced cell survival (Fig. 4C and D). In the presence of 4 μM CdCl₂ and 10⁻⁴ final tincture dilutions, the proportion of fragmented nuclei in hepatocytes was 7% for Carduus marianus and 11% for Chelidonium (Table 5).

    3.6 Cadmium-induced activation of caspases

    Results for caspase-3 activity measurements were similar to those for apoptosis. In HepG2 cells, 3 μM CdCl₂ induced a significant increase in caspase-3 activity within 24 h (Table 6), with a 1.8-fold increase in caspase-3 and a 2.5-fold increase of caspase activity as measured by caspase-3/7 assay. Simultaneous addition of Carduus marianus at a 10⁻⁴ dilution to the culture medium resulted in a decrease of caspase-3 activity to about 1.3-fold, and the 10⁻³ dilution decreased caspase-3 activity to about 1.2-fold, relative to the vehicle-treated controls. Chelidonium was slightly less effective, but still reduced caspase-3 activity significantly in both assays (Table 6). A similar result was obtained for the Hepeel® 10⁻⁴ dilution, which reduced CdCl₂-induced caspase activity in both assays by approximately 40% (Table 6). Aside from Carduus marianus and Chelidonium, none of the other constituent tinctures was effective (not shown), since many HepG2 cells detached or decomposed completely within 30 h of CdCl₂ exposure.

    3.7 Cadmium-induced release of cytochrome C

    The release of cytochrome C from mitochondria of HepG2 cells was significantly higher in the presence of 3 μM CdCl₂ than in unexposed cells, which showed almost no release (Fig. 6). Densitometric analysis revealed a 27-fold increase in cytochrome C in CdCl₂-treated versus vehicle control cells. Hepeel® (10⁻¹) reduced the release of cytochrome C by about 5-fold, and Carduus marianus (10⁻³) reduced it by 7-fold (Fig. 6). Chelidonium was almost as effective as Carduus marianus, while treatment with China showed no effect (data not shown).

    4. Discussion

    Our results demonstrate a strong protective effect of the combination preparation Hepeel® and several of its constituent plant tinctures against cadmium-induced hepatocellular damage in both human hepatoblastoma cell line HepG2 and primary rat hepatocytes. We showed that cadmium-induced hepatocellular damage is effectively counteracted by these agents, thus gaining insight into potential mechanisms of this protective effect, which focus on two aspects: oxidative stress, and occurrence of apoptosis.

    There are conflicting reports in the literature about oxidative stress during cadmium cytotoxicity. While some authors report that cadmium toxicity is due to, or at least associated with, increased oxidative stress and lipid peroxidation (Dudley and Klaassen, 1984; Fariss, 1991; RIkans and Yamano, 2000; Souza et al., 2004a,b; Koizumi et al., 2006), other authors could not detect enhanced lipid peroxidation in response to cadmium exposure in vivo and in vitro (Harvey and Klaassen, 1983; Aydin et al., 2003).

    Concerning the occurrence of apoptosis in response to cadmium exposure our results are consistent with findings in mouse and rat liver (Habeebu et al., 1998; Pourahmad et al., 2001; Li and Lim, 2007) as well as human hepatocytes (Lasfer et al., 2008), and corroborates similar conclusions based on the observation of DNA laddering and other markers of apoptosis in response to cadmium exposure in HepG2 cells (Aydin et al., 2003; Oh and Lim, 2006).

    Our results with DAPI staining also showed that treatment with Hepeel® and the single plant tinctures, which protected against cadmium toxicity, reduced the number of apoptotic nuclei. Furthermore, these agents also inhibited the activation of pre-apoptotic caspases and the release of mitochondrial cytochrome C. Therefore, these results strongly suggest that the most effective single tinctures, Carduus marianus and Chelidonium, are able to counteract intracellular processes other than oxidative stress, such as events leading to caspase activation and subsequent apoptosis, in response to cadmium. Silybin is an active substance in the Carduus marianus tincture, and is known to exert an anti-apoptotic influence in other systems (Singh and Agarwal, 2004; Pock et al., 2006). Thus, silybin may contribute to the protective effects of the tincture. However, direct anti-apoptotic properties of Chelidonium have not yet been described. Interestingly, alkaloids derived from Chelidonium such as chelerythrine and sanguinarine interact with the cytoskeleton (Slaninova et al., 2001), and of these, the alkaloid chelerythrine is an inhibitor of protein kinase C (Herbert et al., 1999). In addition, chelerythrine recently described as an inhibitor of BclXL function, which may help explain the pro-apoptotic effect observed with Chelidonium (Chan et al., 2003). In fact, detailed studies on the molecular interactions of chelerythrine revealed binding sites distinct for the Bcl3 (Bcl-2 homology 3) binding cleft (Zhang et al., 2006). This finding raises the possibility of alternate mechanisms favouring interactions of pro-survival members of the Bcl-2 family. In light of these findings, the concentrations of chelerythrine in our experiments is much lower than the EC₅₀ value for its pro-apoptotic effect (Chan et al., 2003; Maliková et al., 2006). Thus, at low concentrations anti-apoptotic influences of chelerythrine and sanguinarine seem to predominate.

    Therefore, our results strongly suggest that the protective function of Hepeel® against cadmium-induced cytotoxicity results from the synergistic actions of its composite tinctures. The decisive anti-apoptotic influence of Hepeel® may be supported by its antioxidative features that help stabilize cellular GSH content, and consequently the sulfhydryl status of cellular proteins. Further studies are needed to discern whether this protective effect is specific to cadmium toxicity in hepatocytes, or can be generalised to other toxins and cell populations.

    In conclusion, Hepeel® efficiently antagonised cytotoxic and apoptotic effects of the heavy metal cadmium in hepatocyte cell populations. This protective function is likely based on anti-apoptotic influence distinct from anti-oxidative function, but may be rendered more efficient by the synergistic effects of both. These observations add to the list of beneficial effects recently reported with this preparation (Gebhardt, 2003), and support the possible therapeutic use of Hepeel®, particularly for cases of heavy metal poisoning.

    Conflict of interest

    None.

    Acknowledgement

    This work was supported in part by the University of Leipzig (KST 764100100); and Biologische Heilmittel Heel GmbH, Baden-Baden, Germany (97000-050). The author would like to thank Mrs. D. Keller, Mr. F. Struck and Mrs. B. Woite for excellent technical assistance and Dr. A. Gerasimova for valuable comments and editing.

    References

    1. Waalkes MP, Liu J, Diwan BA. Toxicology of cadmium and its damage to mammalian organs. Biomed Environ Sci. 2000;13(1):28–37.
    2. Godt J, Scheidig F, Grosse-Siestrup C, Esche V, Brandenburg P, Reich A, et al. The toxicity of cadmium and resulting hazards for human health. J Occup Med Toxicol. 2006;1:22.
    3. Nordberg G. Application of the critical effect and critical concentration concept to human risk assessment for cadmium. In: Nordberg GF, Herber RFM, Alessio L, Eds. Cadmium in the Human Environment: Toxicity and Carcinogenicity. IARC Scientific Publications; 1992. p. 3–14.
    4. Koizumi TT, Yadov T, Shirakura H, Tatsumoto H, Suzuku KT. Potential mechanism of cadmium-induced cytotoxicity in rat hepatocytes: inhibitory action of cadmium on mitochondrial respiratory activity. Toxicology. 1994;92(2):115–25.
    5. Dudley RE, Klaassen CD. Inhibition of cell proliferation and induction of apoptosis by cadmium chloride in primary cultures of rat hepatocytes and HepG2 cells. Toxicol Appl Pharmacol. 1984;76(3):354–64.
    6. Fariss MW, Reed DJ. Oxidative stress in cadmium toxicity: depletion of cellular glutathione and inhibition of thiol-containing enzymes. Toxicol Appl Pharmacol. 1991;108(2):284–91.
    7. Souza LM, Escobar DC, Clouser MQ, Hernandez E, Gutierrez-Ruiz MC, Moualla SI, et al. Thyroid hormone reduction in rat hepatocytes exposed to cadmium. Ecotoxicol Environ Safety. 2004a;57(1):71–8.
    8. Souza L, Escobar D, de Souza C, Gutierrez-Ruiz M, Moualla S. Cadmium-induced hepatotoxicity: an in vitro model with primary rat hepatocytes. J Toxicol Environ Health A. 2004b;67(11):927–40.
    9. Sarkar MA, Das P, Ghosh RK. Protective effect of zinc against cadmium-induced oxidative stress. Arch Toxicol. 1995;69(2):125–31.
    10. Gebhardt R. Stimulation of liver function and antioxidant activity of Hepeel: an experimental and clinical study. Phytomedicine. 2003;10(6-7):480–6.
    11. Pavlica S, Gebhardt R. Induction of glutathione-S-transferase by Hepeel and single plant tinctures in HepG2 cells. Phytother Res. 2005;19(2):139–2.
    12. Gebhardt R, Faustel H. Determination of GSH content in hepatocytes: methodological improvements. Toxicol Appl Pharmacol. 1997;146(2):179–88.
    13. Gebhardt R, Hope J, Louw L. Cadmium toxicity in primary rat hepatocytes: morphologic alterations and induction of apoptosis. Toxicol Appl Pharmacol. 2000;162(1):32–40.
    14. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265–75.
    15. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malondialdehyde and 4-hydroxynonenal. Methods Enzymol. 1990;186:407–21.
    16. Wang H, Joseph JA. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med. 1999;27(5-6):612–6.
    17. Aydin HH, Devaki R, Karacaali S, Mete N, Alarco U, Batur Y. Oxidative stress and mitochondrial damage in cadmium-treated HepG2 human hepatoma cells. Biol Trace Elem Res. 2003;92(1):43–50.
    18. Ochiai T, Okamoto K, Akihane K, Higure A, Todoroki H, Abe Y, Kikuchi K. Mitochondrial signaling in cadmium-induced apoptosis through down-regulation of caspase-3 activity. Cancer Lett. 2004;203(1):43–50.
    19. Lasfer M, Vidal JD, Biondi L, Bruguière JF, Feldmann C, Reyl-Desmars F. Cadmium induces mitochondria-dependent apoptosis of normal human hepatocytes. Toxicol. 2008;241(1-2):121–26.
    20. Li Y, Lim L. Cadmium-induced apoptosis of hepatocytes is not associated with death receptor-related caspase-dependent pathways in rat. Environ Toxicol Pharmacol. 2006;24(1):231–8.
    21. Habeebu SS, Beltz WF, Shelton J, House DE, Barnett JB. Cadmium-induced apoptosis in mouse liver. Toxicol Lett. 1998;102-103:319–29.
    22. Pourahmad J, Hosseini MJ, Eskandari MR, Eghlidoura S. Role of mitochondrial permeability transition in cadmium-induced apoptosis of rat hepatocytes. Toxicol Appl Pharmacol. 2001;174(2):120–9.
    23. Oh S, Lim CM, Cho YS. Cytotoxic and apoptotic mechanisms of cadmium in mouse hepatocytes in situ. Toxicol Lett. 2006;164(3):325–36.
    24. Chan SL, Coe M, Tan KC, Yang LK, Lee ASY, Flowa H, et al. Identification of chelerythrine as an inhibitor of BclXL function. Cancer Biol Ther. 2003;2(6):599–609.
    25. Slaninova I, Smejkal J, Modrianský M, Hrkal Z. Interaction of chelerythrine with animal and yeast caspases. Toxicol Vitr. 2001;15(3):425–30.
    26. Herbert JM, Augereau JM, Gleye J, Hammanip JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1992;99(3):399–903.
    27. Zhang Z, Wang J, Clerc J, Xu L. Binding of chelerythrine to Bcl-2 homology domain 3: insights into cell survival mechanisms. J Mol Biol. 2006;364(2):544–9.
    28. Maliková JZ, Žárský HB, Holibová Z. Effects of sanguinarine and chelerythrine on the cell cycle and apoptosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006;150(2):112–8.
  • Homotoxicology can play an important role in cancer management

    HOMOTOXICOLOGY AND CANCER

    Homotoxicology can offer an alternative approach to cancer. Recent research in cytology confirms that oncogenesis starts at the cellular level, and progresses over decades before any symptoms or biochemical parameters can be detected. This long process gives the general practitioner a window of opportunity to discuss complementary prevention programs with his or her patients, particularly those with a family history of cancer.

    The extracellular matrix in which cells bathe provides information to the cells, directing their function and activity in the global scheme of things. When this “environment” is contaminated by toxins it passes along faulty information sequences and results in cellular dysfunction. Tasks such as cell division are corrupted. This insidious process is often the conception of oncogenosis. Unless the misinformation leaking from the extracellular matrix is corrected, the misguided processes can continue for decades eventually bearing a tumor. The benefit the practitioner can derive from the slow course of oncogenosis is an opportunity to mediate the process in an attempt to arrest progression. Homotoxicology offers great potential as it works gently to remove underlying toxins that, if accumulated, could, depending on the patient’s constitution, cause cellular chaos and possible neoplasia.

    The latest in cancer research has contributed new evidence about oncogenosis which reveals processes that can possibly be manipulated over time in the hope of intervening the pathogenesis of neoplasia. One such discovery is the theory of maturational arrest compared to dedifferentiation. It has been assumed that tumors arise from dedifferentiation of mature cells. The latest research now reveals that tumors form from partial or complete arrest in differentiation. In their book, “Mechanisms of Disease”, Slauson and Cooper purport that neoplasia is born from cells involved in tissue renewal; they clearly state that: “tumors are composed of neoplasic stem cells and their well differentiated progeny, which form a “caricature” of their tissue of origin.”

    Because homotoxicology’s underlying purpose is to detoxify the body and can be targeted to different systems to detoxify the patient’s affected terrain and redirect healthy tissue renewal, the application of drainage methods with antihomotoxic remedies can be useful in the complementary approach to cancer. Further evidence from research points to the role of certain viruses in the formation of tumors, another avenue for the complementary intervention with antihomotoxic remedies.

    With this new evidence, we see how homotoxicology can play an important role in cancer management.

    Homotoxic physicians use Galium aparine extensively in their approach to cancer. According to German researcher Boericke, Galium aparine as a homeopathic composite, can halt the process of oncogenesis. It favors healthy granulation tissue of ulcers. Leading expert in, and professor of clinical homotoxicolgy, Dr. Ivo Bianchi considers Galium aparine to be highly cleansing and draining of toxins, not only those at the cellular phase of oncogenesis, but in secondary phases of neoplasia. Dr. Bianchi purports that Galium-Heel is highly anti-inflammatory and anti-degenerative. Keeping in mind that the inflammatory process is at the origin of all disease processes and the arrest of maturation seen at the onset of oncogenesis, the remedy Galium-Heel matches the disease process.

    PROTOCOL:

    DR. BIANCHI recommends 20 drops of Galium-Heel morning and night for a minimum of 2 months, to be repeated 3-4 times a year.

    DR. BIANCHI emphasizes the importance of Galium-Heel for people over 40. He recommends that this age group take Galium-Heel for long periods of time: 20 drops morning and night taken daily for several months; repeat 2-3 times a year


    The treatment of cancer is more complicated, but no less conducive to the use of anti-homotoxic remedies. As a general rule, treatment starts with the administration of drainage remedies: Galium-Heel, Lymphomyosot and Glyoxal-comp. are staples.

    Glyoxal-comp. unblocks damaged respiratory processes, mainly by catalyzing enzymes associated with cellular respiration while it is highly neutralizing to toxins released by damaged cellular processes. Unlike Galium-Heel, Glyoxalcomp. should not be given frequently, and it must be allowed time to work. Glyoxal-comp. works slowly but very effectively.

    The type of cancer will define the remedies to use. In general, protocols for draining and eliminating can be initiated for 2-5 weeks before the specific treatment protocol. The draining/detoxifying protocol for neoplasia applies especially well after tumor removal and /or chemotherapy.

    Unlike prevention, the treatment protocol should use the drinkable ampules and be formulated for each patient according to the type of cancer, its affected tissues or organs, and the stage of malignancy.

  • Anti-Viral Remedies for Protection against Viral Diseases, Flu, Communicative Diseases and Prophylactics

    Engystol® is an effective medicine that has been shown to have a dual mode of action that boosts your immune system and together with its antiviral activity fights off flu-like infections and colds:

    Studies have shown that Engystol® does the following in your body:

    • Increases the number and activity of scavenger cells, called phagocytes that remove the virus from your respiratory tract.
    • Reduces the inflammation caused by the infection.
    • Stimulates your immune system to produce antiviral compounds, known as interferons that weaken the virus. Interferons also play a significant role in regulating immune responses.
    • Provides antiviral activity against viruses such as the Rhinovirus type 14, the Adenovirus type 5, and the Respiratory Syncytial Virus or RSV.

    Natural at its core

    Engystol stimulates the body’s initial defense mechanisms and in this way helps to overcome the cold at an early stage. This is ensured among other things by the natural ingredients Swallowwort and Sulfur. Swallowwort, also called Vincetoxicum hirundinaria, has an anti-inflammatory and supporting effect on the immune system. Sulfur acts against the inflammation of the mucous membranes, mainly found in the throat at the beginning of a cold. 


    When should I take Engystol®?

    When you are experiencing an onset of cold or flu-like symptoms, you may take Engystol® more often to combat the virus:

    • Adults and children over 12: In case of acute complaints, dissolve 1 tablet in your mouth every 30 to 60 minutes, no more than 6 times a day.
    • Children 6-11: In case of acute complaints, take 2/3 of a tablet every 30 to 60 minutes, no more than 6 times a day. Dissolve 1 tablet in approx. 150 ml of water. Give your child 2/3 of the amount and discard the rest.
    • Children 1-5: In case of acute complaints, take 1/2 of a tablet every 30 to 60 minutes, no more than 6 times a day. Dissolve 1 tablet in approx. 150 ml of water. Give your child 1/2 of the amount and discard the rest.

    To continue stimulating your immune system after initial symptoms of cold and flu-like infections have been reduced, the following dosage is recommended:

    • Adults and children over 12: Dissolve 1 tablet 3X daily in your mouth.
    • Children 6-11: In case of chronic forms, take 2/3 of a tablet 1 to 3 times a day. Dissolve 1 tablet in approx. 150 ml of water. Give your child 2/3 of the amount and discard the rest.
    • Children 1-5: In case of chronic forms, take 1/2 of a tablet 1 to 3 times a day. Dissolve 1 tablet in approx. 150 ml of water. Give your child 1/2 of the amount and discard the rest.

    Is Engystol® safe?

    Yes. Engystol® is a natural medicine without the side-effect profile of many synthetic cold medications. This makes Engystol® even suitable for children* and elderly as well as at-risk groups such as asthmatic patients.


    Will Engystol® help me get over flu-like infections and colds more quickly?

    Yes. In fact, over 88% of people suffering from a flu or cold found that Engystol® improved their symptoms within the first week of treatment.

    How does Engystol increases body defences?

    Dual Action in prevention of Viral infections

    How is Engystol® different from other medications?

    Most synthetic cold medications focus on treating symptoms as rapidly as possible, by suppressing key immune system components. However, these medications can prolong the recovery process. Engystol® tackles flu-like infections and colds at the root.


    Can I take Engystol® with other medications?

    Yes. Engystol® can be taken with other medication.

    In one study with people with colds and flu-like infections, 77,1% of them using Engystol in combination with other medications (inhalations, analgesics, vitamins and decongestants) reported significant relief in their symptoms within 3 days, compared to 61.7% of people only using synthetic cold medications.


    Other Viral Remedies


    How does Traumeel work?

    The natural approach to regulating inflammation and supporting recovery


    Non-steroidalanti-inflammatory drugs (NSAIDs) are among the most commonly used pain relievers worldwide. NSAIDs are unspecific COX enzyme inhibitors that reduce the formation of prostaglandins, which are triggers of inflammation. NSAIDs include medicines like diclofenac, ibuprofen, ketoprofen and naproxen. In contrast to NSAIDs, the natural multi-component medicine Traumeel® provides both pain relief and support of tissue repair and results in an accelerated healing process. See the difference between NSAIDs and Traumeel®.

    How Traumeel can help?

    • Inflammation is a complex, multifactorial process, which is essential to tissue repair, e.g. after muscle or joint injury. However, excessive inflammation can cause pain and be detrimental to recovery.
    • Cytokines serving as messenger signals within the immune system of the body can either increase (pro-inflammatory cytokines) or reduce (anti-inflammatory cytokines) inflammation.
    • Imbalance of pro-inflammatory and anti-inflammatory cytokines can lead to excessive and prolonged inflammation and pain.
    • Traumeel® restores the balance of pro- and anti-inflammatory cytokine activity.

    Traumeel® has proven ability to relieve pain and inflammation

    According to controlled clinical trials, Traumeel® can reduce pain and inflammation of different causes and at different sites in the body, for instance:

    Treatment of symptoms such as pain and inflammation caused by injuries of various types (sporting, accidents) such as sprains, strains, bruising, haematomas, bone fractures, etc., degenerative processes that progress with inflammation and suppuration of different organs and tissues (for example parodontitis, gingivitis, parodontosis) and of the musculoskeletal apparatus and ligaments (tendovaginitis, bursitis, tennis elbow), osteoarthritis of the hip, knee and small joints

    Acute ankle sprain

    A recent large-scale study has shown that Traumeel® cream & gel was as effective as diclofenac in pain reduction and functional improvement in the treatment of acute ankle sprains. Compared with a placebo, Traumeel® cream was an effective treatment for activity-related ankle sprains, significantly improving mobility and reducing pain.

    Acute musculoskeletal injury

    Compared with a placebo, Traumeel® cream was significantly more effective in restoring muscle function and reducing pain from musculoskeletal injuries.

    Tendon pain

    Compared with diclofenac (an NSAID), Traumeel® cream reduced pain and achieved a significantly faster return to normal activities.

    Enriching the body with the nutrients that it needs:

    Find out which are of your specific interest.

    gastrointestinal health.

    digestive and draining functions.

    liver function support

    balanced solution against iron deficiency.

    specific amino acid composition for the human body in dietology and clinical

    nutritional support for athletes

    normal blood cholesterol levels.

    respiratory system support

    physical and mental well-being in menopause

    your natural boost of energy

    vitamin C supports absorbtion of minerals

    reduce tiredness and fatigue support healthy muscles keep healthy skin

    supports the body’s  natural defenses and  the respiratory tract.

    acid-base metabolism balance body detoxifying functions mental well-being.

    the synergy of 6 active ingredients for a better mental

    protects and detoxifies the gastrointestinal system

    physical and mental fatigue immune system support

    innovative and unique association of 6 exclusive probiotic strains with

    synergistic innovative prebiotic and nutraceutical food supplement for the wellness

    Minor health problems may be caused by poor or unbalanced diet. It is well known that industrial food processing does not often guarantee an adequate intake of nutrients essential to maintain our health and wellbeing.

    Guna Laboratories have developed “physiological nutraceuticals”, a unique line of innovative and specific nutritional supplements that allow to maintain the normal physiological functions by providing a well-balanced intake of carefully selected nutrients.

  • Percentage of People using Alternative and Homeopathic Medicines

    Sometimes shortened to CAM – is a system of healing which encompasses variety of practices, theories, beliefs and modalities. These methods can often be used by themselves or along with orthodox medicine in treatment or in prevention of a disease in Human and Veterinary patients.

    % of population using:Complementary medicineAcupunctureHomeopathyOsteopathy chiropracticHerbal medicine
    Belgium3119561931
    Denmark23122823No info
    France492132712
    Germany46No infoNo infoNo infoNo info
    Netherlands201631No infoNo info
    Spain25121548No info
    UK2616163624
    USA3433309
    Comparative usage of complementary medicine (Fisher and Ward, 1994)

    Homeopathy is a system which can be used inline with other forms of treatments. Everything that can be known about the patient can be used to consider the remedy. It is referred to as holistic therapy because of its approach to heal the patient and not the disease.


    Popularity of Homeopathy is increasing significantly due to a lot of push factors such as delayed appointments with GPs, lack of time spent with the doctors assessing patient, diagnostical delays in hospital settings, disenchantment using antibiotics, ever increasing side effects and antibiotic resistance.

  • THE COLLAGEN MEDICAL DEVICES IN THE LOCAL TREATMENT OF THE ALGIC ARTHRO-RHEUMOPATHIES

    REVIEW OF THE CLINICAL STUDIES AND CLINICAL ASSESSMENTS 2010-2012

    INTRODUCTION

    Reliable epidemiologic data recorded in Italy (Mannaioni et Al., 2003) and in Europe [Jordan et Al., 2003-European League Against Rheumatism (EULAR)] show that 15-20% of the general population suffers from pathologies involving the osteo-arthro-myo-fascial Apparatus (better defined as arthro-rheumopathies), representing 70% of the patients with chronic pain.


    – In the near future, these data will probably undergo an increase, especially due to increased life expectancy, overall average increase in body weight, greater propensity to inactivity amid people above 50, higher incidence of amateur sports activity and consequent traumas (mostly among people aged between 20 and 45), overuse of NSAIDs and unhealthy diet, basically high in proteins. The arthro-rheumopathies (connective tissue inflammatory and/or degenerative diseases) are all characterized by collagen disorders.

    Collagen’s physiological tissue organization and quantitative and qualitative composition – which dramatically decrease from = 60 years of age (Heine, 2009) – determines the organoleptic characteristics of connective tissues. – Collagens are merged into a vast family of structural proteins of the extra-cellular matrix having unique and peculiar characteristics, also from the phylogenetic point of view (in Milani, 2010).

    Up to the present more than 30 genetically
    distinct varieties (Types) of collagen have been identified.Genetic alterations of some Types of
    collagen determine complex and paradigmatic phenotypes (alterations in the collagen Type I: e.g. osteogenesis imperfecta; Type I, III, V: e.g. Ehlers-
    Danlos syndrome; Type IV: e.g. Alport syndrome; Type II, XI: e.g. cartilage genetic diseases). The fibrillar collagen Type I (COL1A1 and COL1A2 coding genes) is the most abundant ubiquitous protein in adult humans, accounting for 90%of the total collagen: it is involved in the

    A

    A – Continuity of collagen fibers in the ligament of adult rats.
    Electron Microscope images from Provenzano P.P. and Vanderby R. Jr. – Collagen fibril morphology
    and organization: Implication for force transmission in ligament and tendon. Matrix
    Biology 25(2006) 71-84.

    composition of the main connective tissues and represents the bulk of certain structures such as skin, dentine, cornea, joint capsules, ligaments, tendons, aponeurotic layers and fibrous membranes. – In the tendons, for example, collagen Type I = 97%; elastin = 2%; proteoglycans = 1-5%; inorganic components (Cu, Mn, Ca) = 0.2% (Jozsa and Kannaus, 1997; Lin et Al., 2004); in ligaments, collagen Type I = 85% (Frank, 2004; Vereeke et Al., 2005). The in vivo fibrillogenesis is a multi-step process involving both the intracellular compartment and the extracellular one, defined by tenocyte (a very specialized fibrocyte) (FIG. 1). – The tenocyte, in addition to collagen Type I, also synthesizes the matrix proteoglycans (PGs) and the metalloproteinase (MMP) 1-interstitial which is involved, together with the MMP8-neutrophil, in the degradation of the fibrils, either because old or damaged by the inflammatory/traumatic process (Birk et Al., 1995; Canty, 2004). The MMP1 is primarily involved in the processes of fibrillo- (collagen)-lysis: the study of Maeda et Al. (1995) highlights a very high concentration of MMP1 in the synovial fluid of patients with rheumatoid arthritis, which is related to the degree of inflammation (reliable marker of the disease status). Provenzano andVanderby Jr. (2006) ), using the electron microscope, exhibit a wide range of very impressive photographs proving that healthy adults collagen fibrils (FIG. 2A) are very precise, parallel to each other, continuous and laid longitudinally along the main axes of the anatomical structures to which they belong and which characterize, transmitting the force directly and not through the PGs bridges.

    – The collagen turnover is very slow. The mechanical failure and the presence of free radicals can increase the degenerative process, causing a spontaneous, slow and imperfect neofibrillogenesis: the process of spontaneous repair leads to the neoformation of disordered, twisted, juxtaposed, discontinuous fibers, (FIG. 2B), morphologically much more similar to the fetal ones rather than the adult ones (Provenzano et Al., 2001). It also leads to increased vascularization and increased deposits and clusters of inflammatory cells. These phenomena all contribute to the further weakening of collagen Type I (Shrive et Al., 1995; Frank et Al., 1999) and to the increased synthesis of collagen Type III (Liu et Al., 1995; Hsu et Al., 2010), which is functionally much less suitable.
    B

    B – Post-traumatic repair of the collagen texture.
    Electron Microscope images from Provenzano P.P., Hurschler C., Vanderby R. Jr. – Connect.
    Tiss. Res. 42:123-133, 2001.

    During the fibrillogenesis process, the PGs play a crucial role in guiding and stabilizing neofibrils, assisted by the SLPR (Small Leucine Rich Proteoglycans) (Jepsen et Al., 2002), represented above all by decorin, lumican, and fibromodulin. The rare overt genetic alterations of these 3 small PGs affect distinct phenotypes, clinically severe. – Minor alterations with variable penetrance and expressivity are probably not diagnosed and are the primary cause of highly pathologically susceptible conditions: collagen fibrils altered in shape and diameter which affect the joints and posture long before the physiological decay. – I conclude these brief topics on collagen, which supplement and detail what presented in a previous publication (Milani, 2010) to which I refer, indicating that collagen is also a template for bone mineralization, which promises new and revolutionary solutions in Orthopedics and Traumatology.

    The anatomical structures composing the extra-articular environment of the joints – with containing and stabilizing functions – are represented by:

    1. joint capsule, ligaments and fibrous membranes (“direct hold”);
    2. tendons and muscles (“indirect hold”).

    These elements – which unite and wrap the distal end of a bone and the proximal end of the adjacent bone (superoinferior) (bone segments in connection) – are the actors of the containment-stabilization and of the joint mobility.
    – Although anatomically distinct and functionally different, these structures are in close continuity (contiguous or overlapping anatomical planes; some collagen fibers of each structure merge with the neighboring ones) to form an elastic-stretch sleeve performing primarily two functions:

    1. Articular establishment in static / dynamic physiological position;
    2. Articular mobility with maximum range.

    FIGURE 3 shows as exemplification the fibrous structures of the extra-articular environment of the elbow.
    – In addition to the extra-articular structures, few joints also have intra-articular intrinsic ligaments that connect two skeletal segments inside the joint capsule (e.g. cruciate ligaments of the knee joint, coxofemoral round ligament).
    – The extra-articular structures (primarily: joint capsule, ligaments and tendons) are constituted by collagen Type I: the quality and the quantity of this protein ensure a physiological joint movement, repeated over time and optimal movement.

    Progressive depletion and / or damage to organoleptically suitable collagen Type I is produced by aging (discrepancy between neofibrillogenesis and fibrillo-lysis), misuse or disuse of the joints, traumas aggravated by the coexistence of internal diseases and – in some age groups – even by vitamin deficiencies (vitamin C, but also vitamin A and E), copper
    deficiency, noble proteins deficiency, and the use / abuse of drugs (particularly corticosteroids).
    – In particular, Elder et Al. (2001), Warden (2005), and Warden et Al. (2006) show that NSAIDs COX-2 inhibitors inhibit the healing of injured ligaments, leading to the lack of mechanical strength (imbalance between joint stability and mobility) and causing extra- and intra-articular damages. The trial of these drugs demonstrates unequivocally that the anti-inflammatory benefit in the short term is converted into serious harm in the medium and long term.
    – Fournier et Al. (2008), and Ziltener et Al. (2010) maintain that the use of NSAIDs in the treatment of periarticular soft tissues (ligaments, capsule) should be very limited in time, or absent.

    A – Left elbow joint, front.
    B – Right elbow joint, front.
    The containing and stabilizing
    structures of the elbow joint are
    represented by extra-articular
    connective-collagen Type 1 structures.
    They are represented by:
    – ulnar collateral ligament (A, B);
    – radial collateral ligament (A, B);
    – anular radial ligament (A, B);
    – sacciform recess (A);
    – joint capsule (lifted in A; B);
    – brachial biceps tendon (B).
    All these structures allow the
    large variations in flexion, extension
    and torsion of the forearm on
    the arm.
    – Images translated and elaborated by the
    author from W. Spalteholz – R. Spanner,
    Atlante di Anatomia Umana. Società
    Editrice Libraria (Vallardi) – Milano, 5th Italian
    edition (1962) in the 16th German edition
    (1959-61); 1st Vol.; pp. 232-3.

    Barton and Bird (1996) indicate the laxity or hyperlaxity of anatomical structures as the most important cause of pain of one or more joints. The quoted authors’ studies follow those by:

    • Rotes-Querol (1957), which identified joint laxity as the main factor of altered posture;
    • Teneff (1960), indicating the clinical significance of congenital
      joint laxity;
    • Donayre and Huanaco (1966), which show that the orthopedic
      joint laxity is the cause of many diseases (defined
      by the authors as “arthrocalasis”).
      Recently:
    • Philippon and Schenker (2005) show high incidence of
      coxofemoral traumas in athletes with femoral laxity;
    • Paschkewitz et Al. (2006) describe the generalized ligament
      laxity associated with proximal dislocation of the tibio-
      peroneal joint;
    • Hauser and Dolan (2011), indicate in joint instability and
      unhealed ligament injuries the primary cause of osteoarthritis.

    These are just some historical data and the most recent ones among those that can be extrapolated from the available literature on the topic which indicate that the joint hypermobility due to deficiency of joint containment (ultimately: deficiency of collagen Type I in the extra-articular environment) is the primary cause of the arthropatic etiology.
    It is necessary to distinguish between joint hypermobility due to impaired containment from the one due to paraphysiological laxity, such as:

    • in childhood (Cheng et Al., 1993; Bird, 2005; Simpson, 2006);
    • in females, especially during the menstrual cycle (Schultz, 2005);
    • In individuals belonging to African (Beighton et Al., 1973) and eastern (Walker, 1975) anthropological varieties,

    and the one due to joint instability of various pathological degree, which starts when the contiguous bone segments forming a joint do not respect the optimal axes and – consequently the angles among them. Paradigmatic examples – not the only ones, though – of such situations are:

    • valgus/varus tibio-femoral joint (FIG. 4) and valgus/varus coxofemoral joint,
    • the extra/internal rotation of the head of the femur in the acetabulum,
    • the lordosis/kyphosis of the rachis segments,
    • cavus/flat foot.

    Situations that can worsen joint hypermobility are paraphysiological variations and real alterations of the diaphyseal shape, the alteration of the muscle tone and abnormal proprioception.

    All the above conditions necessarily lead to pathological osteo-cartilaginous hyperload which cause the overuse processes. The bone reacts with the production of marginal osteophytes, subchondral bone cysts, subcortical hardenings or deformities and/or epiphyseal osteopenia.

    These extra-physiological forces cause, especially in the load joints, slippage of the adjacent bone heads, which are anteroposterior, medium-lateral and rotational of greater or lesser severity.

    – In such situations the loose structures of the extra-articular environment are exposed to mechanical stress: the pain due to extra-articular cause is added to the one due to intra-articular cause (which is frequently inflammatory), thus aggravating the status and prognosis of the disease.

    The organism performs mechanisms of local and remote compensation by establishing the activation (hyperactivation) of ascendants and descendants muscle-proprioceptive chains which only rarely get the desirable effect: the control of the vascular tone is unintentional and self-organizing, at central and peripheral level.

    – Currently, the treatment of arthro-reumopaties offers different options; it includes different, unique treatments or – more frequently – a combination of:

    • non-pharmacological treatments (e.g. ultrasound therapy, magnetic therapy, laser therapy, TENS, acupuncture, moxibustion, etc.);
    • conventional pharmacological treatments [e.g. COXIB, NSAIDs, paracetamol, corticocosteroids (the latter also intra- articularly injected)];
    • unconventional pharmacological treatments [e.g. specific medicines formulated by Homeopathy, Homotoxicology (the latter also via intra-articular injection, periarticular injection, mesotherapy, homosiniatry treatment), Physiological Regulating Medicine, Herbal Medicine];
    • physical-rehabilitation treatments (see review by Di Domenica et Al., 2004);
    • surgical treatment: mobile (prosthesis, especially hip, knee, shoulder) or fixed (arthrodesis).

    Symptomatic slow-acting treatments include viscosupplementation with hyaluronic acid (see review by Bellamy et Al., 2008) or with hylan G-F 20 (derived from the hyaluronic acid) (see review by Conrozier and Chevalier, 2008), administered mainly via injection into the knee, hip and shoulder. They are viscous lubricants whose prevailing action is supplementary and cushioning.

    The viscosupplementation replaces the (usually degraded) hyaluronic acid of the synovial fluid of the joints of the pa- tients affected by osteoarthritis.

    The hyaluronic acid is mostly used to inject the knee in or- der to treat gonarthrosis.

    Nevertheless, the members of the EULAR (European League Against Rheumatism) Committee for clinical trials on osteoarthritis of the knee met in 1998 and came to the con- clusions that the hyaluronic acid and symptomatic slow-ac- ting antiarthritic drugs have modest efficacy in gonarthro- sis. Moreover, they stated that the patients who may benefit from this therapy are hardly identifiable and that pharma- coeconomic data are uncertain. The opinion of 21 experts has placed the use of the hyaluronic acid for the treatment of gonarthrosis in 13th place out of 23 entries (Pendleton et Al., 2000).

    • Since 2010, also the treatment of algic/degenerative dis- eases of the musculoskeletal system takes advantage of the

    use of the injectable Collagen* Medical Devices (MDs) (Gu- na Laboratories, Milan – Italy).

    The Collagen MDs can be used alone (e.g. MD-Lumbar: low back pain with high arthritic imprint), or – more frequently variously mixed according to the patient’s clinical and func- tional needs (e.g. MD-Lumbar + MD-Neural: low back pain with algic nerve imprint; MD-Lumbar + MD-Muscle: low back pain with prevailing myo-fascial imprint).

    The Collagen MDs are applied locally through:

    1. periarticular injections
    2. intra-articular injections (obviously in the joints allo- wing a clear intra-articular approach: knee, hip, shoul- der)
    3. subcutaneous and/or intradermal injections (in trig- ger points, in spontaneously painful points, in points whe- re average digitopressure causes pain, in local acupunc- ture points, etc.).

    or systemically:

    – intramuscular injections (into muscle trigger points), and in supportive treatment (mainly at home).

    The 13 Collagen Medical Devices are produced from der- mal tissue of swine origin (trophism) + ancillary excipients of natural origin allowing an efficient and specific positio- ning on site (tropism).

    The ancillaries were selected according to different criteria such as: traditional use, dedicated literature, clinical eviden- ce, quality profiles, etc.

    The swine’s dermal tissue contains » 50% of collagen Type I (Gly = 22.8%; Pro = 13.8%; OH-Pro = 13%).

    • The purpose of the in situ injections of the Collagen MDs is essentially structural.

    From 2010 to 2012 10 clinical trials on humans were car- ried out, involving most of the treatable anatomical districts with Collagen MDs: 3 gonarthrosis, 1 patello-femoral arth- ropathy, 2 coxarthrosis, 2 shoulder pain, 1 PMID (Painful Mi- nor Intervertebral Dysfunctions) of cervical rachis, 1 acute lumbar back pain.

    • In the following pages it is presented the synopsis of the experiments; the Authors’ conclusions of the 10 trials are faithfully reported.

    ►     EFFICACY AND SAFETY OF THE GUNA MDs INJEC- TIONS IN THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE

    Authors: Rashkov R., Nestorova R., Reshkova V.

    • Clinical Assessment presented at the Bulgarian National Congress of Rheumatology – Pravets (October 2011), at the European Congress on Osteoporosis and Osteoarthritis – Bor- deaux (F) (March 2012), and at the 3rd Bulgarian National Congress on Osteoporosis and Osteoarthritis – Sandanski (No- vember 2012).

    Experimental sites: Rheumatology Clinic of the Medical University of Sofia, Rheumatology Center St. Irina (Sofia – Bul- garia).

    Pathologies considered: symptomatic gonarthrosis (Kellgren- Lawrence* Rx grade II-III) without aftereffects of the periar- ticular soft tissues.

    Outcomes

    1. assessment of pain at rest and during movement before and after treatment;
    2. assessment of the Lesquesne Algofunctional Index** be- fore and after treatment;
    3. effectiveness of the MDs used (evaluation by the patient and by the physician).

    Inclusion/exclusion criteria: stated.

    Patients enrolled: 28 (12 M, 16 F, aged 55-70).

    Treatment: MD-Knee, 1 ampoule + MD-Muscle, 1 ampou- le: 2 intra-articular injections/week for 2 consecutive weeks

    + 1 intra-articular injection/week for the next 6 weeks (total: 10 injections in 2 months).

    Results

    Statistically significant reduction of pain (VAS *** = 0-10) at rest (maintained even 30 days after the end of the therapy) and during movement (VAS = 0-10) (maintained even after the end of the therapy) (TABLES. 1, 2). Statistically significant improvement of the indicators of the Lesquesne Algofunctional Index (TABLES 3, 4).

    Authors’ conclusions:

    1. Intra-articular administration of MD-Knee + MD-Muscle in gonarthrosis Kellgren-Lawrence Rx grade II-IIII reduces si- gnificantly pain at rest and during movement and improves the functional activity of patients, who assessed excellent + good in 65% of cases.
    2. The effect persists even after treatment.

    There were no adverse effects in any case.

    ► EFFECTIVENESS OF THE GUNA COLLAGEN MDs INJECTIONS   IN   PATIENTS   WITH  GONARTHROSIS, ANALYSED CLINICALLY AND WITH ECOGRAPHY

    Authors: Nestorova R., Rashkov R., Reshkova V., Kapandjieva N.

    • Clinical Assessment presented at the 9th Central Congress of Rheumatology (CECR 2012) 3rd Annual Meeting of the Polish Rheumatologists – Krakow (Poland) (September 2012), and at the European Congress on Osteoporosis and Osteoarthritis – Bordeaux (F) (March 2012).

    Article published in Rp./Orthopedic 2011/3, Medicine and Sport 2011/4 and PRM 2012; 37-39.

    Experimental sites: Rheumatology Center St. Irina (Sofia); Rheumatology Clinic MBAL “St. Ivan

    Experimental sites: Rheumatology Center St. Irina (Sofia);

    Rheumatology Clinic MBAL “St. Ivan Rilski” (Sofia); Rheu- matology Center MBAL – Rousse (Bulgaria).

    Pathologies considered: symptomatic gonarthrosis (Kellgren-Lawrence* Rx grade III-IV) with aftereffects of the periarti- cular soft tissues.

    Outcomes

    1. assessment of pain at rest and during movement (VAS = 0-10; Lesquesne Algofunctional Index**);
    2. ecographic evaluation before treatment, after 30 days and at the end of the treatment;
    3. evaluation of effectiveness of the MDs used.

    Inclusion / exclusion criteria: stated.

    Patients enrolled: 35 (aged 62-79).

    Treatment: MD-Knee, 1 ampoule + MD-Matrix, 1 ampou- le: peri-articular injections / week for 2 consecutive weeks

    + 1 peri-articular injection /week for 6 more weeks (total: 10 injections in 2 months).

    Results

    1. Statistically significant reduction of pain (VAS*** = 0-10) at rest (maintained even after the end of treatment) and du- ring movement (maintained even 30 days after the end of treatment) (TABB. 5, 6).
    2. Statistically significant improvement of all indicators of the Lequesne Algofunctional Index (examples in TABB. 7, 8).
    3. 60% of patients do not have any edema; 30% achieved a reduction of edema

    – Authors’ conclusions:

    1. ) Intra-articular administration of MD-Knee + MD-Matrix in gonarthrosis Kellgren-Lawrence Rx grade II-IIII reduces si- gnificantly pain at rest and during movement and improves the functional activity of patients.
    2. The effectiveness of treatment was evaluated as excellent

    + good in 68% of patients and 72% of physicians.

    • Periarticular edema improves in 90% of cases as proven by ecography.
    • The effect is maintained even after treatment.

    The analysed MDs have a very high safety profile.

    ►     APPLICATION AND ASSESSMENT OF EFFICACY OF COLLAGEN INJECTIONS GUNA MDs IN GONARTHRO-SIS

    Author: Boshnakov D.

    – Clinical Assessment presented at the XIX Days of Bulga- rian Orthopedics and Traumatology, Tryavna, (September 2012).

    Experimental sites: Saint Anne University Hospital, Varna(Bulgaria).

    Pathologies considered: gonarthrosis.

    Outcomes

    1. assessment of pain at rest and during movement (VAS = 0-10);
    2. assessment of Lequesne Algofunctional Index for:

    a.pain when walking; b.maximum walking distance (in me- ters); c.daily activities;

    3. assessment of efficacy of treatment from the patient’s view- point.

    Inclusion/exclusion criteria: unstated.

    Patients enrolled: 14 (8 M; 6 F; aged 51-72).

    Treatment: MD-Knee, 1 ampoule + MD-Muscle, 1 ampou- le: 2 intra-articular and peri-articular injections/week for 2 consecutive weeks + 1 intra-articular and peri-articular in- jection/week for the following 6 weeks (total: 10 treatments in 2 months).

    Results

    1. Pain at rest: VAS from 2.85 at treatment start (moderate pain) to 0.95 at the end of treatment (no pain) (TAB. 9).
    2. Pain when moving: VAS from 7.3 at treatment start (un- bearable pain) to 3.5 at the end of treatment (moderate/se- vere pain) (TAB. 10).
    3. Lequesne Algofunctional Index: from 1.6 at treatment start to 1.1 at the end of treatment (TAB. 11); maximum walking dis- tance from 100-300 meters before treatment (5.2 score) to 400-700 meters after treatment (3.6 score) (TAB. 12).

    Author’s conclusions:

    1. Intra-articular injections of Collagen MDs improve: a) lo- calized pain; b) pain at movement; c) joint mobility.
    2. Intra- and peri-articular injections improve the patients’ functional activity and quality of life.
    3. The injections of Collagen MDs are a new and effective method to treat gonarthrosis.

    ►     PATELLO-FEMORAL CHONDROPATHY TREATED WITH MD-KNEE + ZEEL® T TRANSMITTED WITH O2 VERSUS

    NIMESULIDE + CHONDROITIN SULPHATE

    Author: Posabella G.

    • Clinical trial presented at the Meeting Sport Medicine, the challenge for Global Health – Rome (September 2012).

    Article published in La Med. Biol., 2011/3; 3-11, and in PRM 2012/1; 3-10.

    Pathologies considered: patella-femoral chondropathy stage I-II-III according to Kellgren-Lawrence.

    Outcomes

    assessment of clinical response (analytical WOMAC****; Le- quesne Index) after administering MD-Knee + Zeel® T trans- mitted with hyperbaric O2 (Group A) versus nimesulide + chondroitin sulphate (Group B).

    Inclusion/exclusion criteria: unstated; randomization.

    Patients enrolled: Group A, 20 [15 M, 5 F; average age 46.4 years (31-66)]; Group B, 20 [15 M, 5 F; average age 46.9 years (28-65)].

    Treatment: Group A – MD-Knee, 1 ampoule + Zeel® T, 1 ampoule, both applied onto the knee skin and transmitted with hyperbaric O2, 1 application/week.

    Group B – nimesulide in 100 mg sachets + Condral (galaco- tosaminoglucuronoglycan sulphate sodium salt) 400 mg, 1/die per os.

    Results

    • After the first week of treatment the patients of both groups (A; B) showed a reduction of the total WOMAC score com- pared to baseline, even if not statistically significant.

    WOMAC Group A = 50 points – Lequesne Index = 17.05 WOMAC Group B = 54 points – Lequesne Index = 17.9

    -Second week

    WOMAC Group A = 47 points WOMAC Group B = 53 points

    -Third week

    WOMAC Group A = 44 points WOMAC Group B = 51 points

    -Sixth week (1st follow-up) WOMAC Group A = 41 points WOMAC Group B  = 50 points

    -Twelfth week (2nd follow-up)

    WOMAC Group A = 39 points – Lequesne Index = 10.4 WOMAC Group B = 47 points – Lequesne Index = 15.3

    Author’s conclusions:

    1. Both Groups of patients (A; B) showed a considerable im- provement of pain and functional limitation.
    2. The data show a more rapid clinical and functional im- provement in the patients of Group A compared to the pa- tients of Group B.
    3. No side effects in the patients of Group A.

    – For comparative analysis of the 4 clinical trials on the osteoarthritis of the knee see TAB.13.

    ►     INTRA-ARTICULAR ADMINISTRATION OF MD-HIP IN 7 PATIENTS AFFECTED BY HIP OSTEOARTHRITIS UNRE-

    SPONSIVE TO VISCOSUPPLEMENTATION.

    -SIX MONTH MULTICENTER TRIAL

    Authors: Migliore A., Massafra U., Bizzi E., Vacca F., Tormenta S.

    – Clinical trial presented at the International Symposium Intra Articular Treatment; Rome (October 2011).

    Experimental sites: UOS (Simple Operating Unit) of Rheu-

    matology – San Pietro Fatebenefratelli Hospital, Rome. Pathologies considered: osteoarthritis X-Ray I-III stage ac- cording to Kellgren-Lawrence affecting the hip joint unre- sponsive to viscosupplementation with hyaluronic acid (6 pa- tients) or hylan (1 patient) (2 ultrasound guided injections at least).

    Outcomes

    1. assessment of efficacy using VAS scale and Lequesne al- gofunctional Index;
    2. NSAIDs consumption before treatment and during follow- up;
    3. safety profile of MD-Hip.

    Patients enrolled: 7

    Treatment: MD-Hip (2 ampoules = 4 ml), 1 ultrasound gui- ded intra-articular injection.

    Results

    1. VAS of osteoarthritis pain = from 6.15 (before treatment) to 4.23 (after 3 months), to 4.23 (after 6 months).
    2. Lequesne Index = from 1.94 (before treatment) to 5.9 (af- ter 3 months), to 5.83 (after 6 months).
    3. NSAIDs consumption = from 7.57 (before treatment) to 4.25 (after 3 months), to 5.78 (after 6 months).

    –  Author’s conclusions:

    1. MD-Hip showed to be effective (all the average values of the results at 3 and at 6 months after the last treatment have been statistically significant) and safe in patients affected by hip osteoarthritis unresponsive to viscosupplementation.
    2. The data suggest that the results can be evident from the very first injection and are stable for 6 months.
    3. The preliminary data offer new research opportunities in the field of intra-articular therapy.

    ►     EFFICACY OF INJECTIONS MD-HIP AND MD-MATRIX IN TREATMENT OF COXARTHROSIS.

    • CLINICAL AND ULTRASONOGRAPHIC EVALUATION

    Author: Tivchev P.

    Article published in Bulgarian Journal of Orthopaedics and Traumatology. Vol 49/2012; 123-8

    Experimental sites: Serdika Hospital (Sofia); Deva Maria Hospital (Bourgas – Bulgaria)

    Pathologies considered: x-Ray stage I-II-III hip osteoarthritis according to Kellgren-Lawrence.

  • Progressive Auto-Sanguis Therapy according to Reckeweg

    Introduction and remarks on theoretic aspects

    Medical history indicates autohemotherapy’s effects to have first been recognized as a result of the following observation: in persons having sustained blunt traumata with haematoma formation, other affections were also discovered to vanish during the course of haematoma absorbtion. Consequently, therapy with the patient‘s own blood (autohaemotherapy) initially consisted of withdrawing a small quantity of blood from the patient and immediately re-introducing it through intramuscular, hypodermic injection. In this manner, an artificial hematoma was created. The conjecture then was that the injection of one’s own blood would activate defensive powers which, in turn, would combat the ”forces of illness within the blood.” Since then, autohemotherapy has been modified and perfected in multifarious ways, yet in actual practice, the original form of autohaemotherapeutic treatment – as irritation therapy, reversal therapy, non-specific excitation, or stimulation therapy – still finds application in numerous individual cases (e.g., in treatment of acne) with highly successful results.

    Progressive auto-sanguis therapy according to Reckeweg is autohaemotherapy in a specialized form. Developed from the fundamentals of homoeopathy in conjunction with Reckeweg’s homotoxicological principles, this technique has proven in practical experience to be reliable and exceptionally effective in treating an extremely wide variety of chronic and degenerative diseases including bronchial asthma, eczema, hepatic damage and numerous other disorders (see also ”Empirically-Proven Indications”).

    According to the teachings of Reckeweg’s Homotoxicology, virtually every illness may be defined as either a defensive reaction by the organism against toxins or as the expression of toxic damage. It follows, therefore, that the blood of each patient  contains those pathogenic poisons (homotoxins) typical for the disease from which that patient suffers. Through withdrawing a patient’s blood, homoeopathically potentizing it over several levels and subsequently re-introducing it by means of hypodermic injection, Reckeweg holds that precisely these pathogenic poisons undergo modification to yield a homoeopathically active therapeutic agent ideal for application in stimulation therapy. In keeping with the Arndt-Schulz Law in the sense of the inverse effect, this agent stimulates the bodily defense systems, thus increasing detoxification and promoting the healing process.

    In accordance with Bürgi’s Principle, the addition of appropriate homoeopathic injection preparations intensifies efficacy of the potentized auto-sanguis blood to an even higher degree. When potentizing the patient’s blood during administration of progressive auto-sanguis therapy, therefore, it has proven expedient to employ the homoeopathic preparation which is therapeutically indicated in each individual patient’s case. In summary, progressive auto-sanguis therapy is treatment designed to exert a counteractive effect against exogenic and endogenic homotoxins (including toxic deterioration products from the body’s own cells), thus promoting the healing of  chronic disease in a manner harmonious with the laws of nature.

    Also discussed in Homotoxicology are further mechanisms of action which play a role in auto-sanguis therapy, the homoeopathic inverse-effect exerted against both auto- antibodies and antigen-antibody reactions in particular. This effect is due to a complement factor which, as a component of the patient’s own blood, is automatically injected in increasing degrees of attenuation during the course of treatment (the so- called complement-inverse-effect; at the 4th level, potentizing of the blood reaches a degree which approximately corresponds to that of C4!).

    This would also explain the positive effects in the area of desensitization/hyposensitization which progressive auto-sanguis therapy is frequently observed to achieve in cases of auto-aggressive disease. One must add, however,  that no major scientific studies exist on the subject at this time. Presented here, rather, are the results of hypothetical deliberation based on the positive observations made during the course of daily medical practice.